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CHAPTER 1 
GENERAL INTRODUCTION 
1 
1.1. HEMOPOIESIS 
1.1.1. Pluripotent stem cells 
Most of the mature blood cells have a limited lifespan and need to be replaced 
constantly throughout life. This process of blood cell formation, termed hemopoiesis, 
is enormous in scale. Some 2 x 1011 erythrocytes and 1.2 x 1011 neutrophils are 
produced each day. Apart from this large production hematopoiesis has to render 
cells of eight distinct cell lineages, i.e.: erythrocytes, platelets, neutrophils, eosinophils, 
basophils, monocytes, B- and T-lymphocytes. It is generally accepted that all mature 
blood cells, including lymphocytes, originate from common pluripotent hemopoietic 
stem cells (PHSC) located in the bone marrow in man and also in the spleen in mice. 
(Till JE & Me Culloch 1961, Van Bekkum, 1977, Quesenberry et al., 1979; Ogawa et 
al, 1983)(fig 1). Apart from PHSC and their progeny, precursors of tissue mast cells 
(Kitamura et al., 1971), osteoclasts (Ash et al., 1980), Kupffer cells (Van Furth, 1980) 
and dendritic cells (Steinman et al., 1974) are present in the bone marrow. Attempts 
to purify stem cells have led to the recognition of subpopulations of stem cells with 
different self-renewal, proliferation and differentiation capacities (Visser et al., 1984, 
Ploemacher and Brons 1988). The stem cell compartment is heterogeneous with 
regard to self-renewal and proliferation capacity (Simonovitch, 1963; Worton et al, 
1969) and there is a hierarchy of stem cells depending on the number of previous 
divisions. In later publications evidence came available that after a higher division 
rate the cells become more committed to differentiation, whereas the stem cells with 
a low division rate still have the largest proliferative capacity (Rosendaal et al., 1979; 
Mauch et al, 1980; Hodgson et al, 1984). The self-renewal capacity of the stem cell 
compartment is extensive and probably does not decline during the normal life-span, 
but may decrease following extensive stress to the marrow (Mauch et al, 1988). 
1.1.2. Models of stem cell renewal and commitment 
Several models have been proposed for the mechanism of stem cell self-renewal and 
commitment. Till and McCulloch (1964) postulated a stochastic model in which the 
decision of a stem cell to either renew itself, or yield daughter cells committed to 
differentiation, is governed by probability rules. Trentin (1970) introduced the 
hemopoietic inductive microenvironment (HIM) model implying that commitment of 
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Figure 1. Scheme of normal hemopoiesis and interactions of the colony stimulating 
factors and interleuldns with hemopoietic cells. CFU = colony forming unit; BFU = 
burst forming unit; IL = interleuldn; CSF = colony stimulating factor; Epa = erythro-
poietin. Adapted from Clark SC and Kamen R The human hematopoietic colony-
stimulating factors. Science 1987; 236: 1229. 
3 
pluripotent hemopoietic stem cells to monopotent progenitors is determined by a 
specific inductive microenvironment surrounding the stem cell. However, the obser-
vations by Magli et al. (1982) on the transient nature of early colonies have presented 
the need for reinterpretation of the experimental data on which the IDM model was 
established. In a third model it was proposed that the regulation of differentiation is 
controlled by humoral factors. The "stem cell competition" model by Van Zant and 
Goldwasser (1977,1979) is an example of this hypothesis. Their data suggested that 
humoral factors play an active role in stem cell commitment. However, this model has 
not gained much support. Therefore, the nature of stem cell commitment remains 
obscure. Evidence exists indicating that under stress situations, such as bacterial 
infections or blood loss, mono- and bipotential progenitor cell populations amplify 
and show higher than normal levels of proliferative activity (Schooly et al, 1965; 
Lange et al, 1969), whereas the early pluripotent progenitor cells are not triggered 
into cell cycle (Bruce et al. 1964; Hara et al, 1977). It has been shown that under 
these conditions humoral factors with stimulatory activity on the proliferation of 
hematopoietic cells are produced (Watari et al., 1989). The first humoral factors that 
were reported to stimulate the proliferation of stem cells were 13-adrenergic agents 
(Byron et al, 1972). More recently it has been shown that the colony stimulating 
factors, described in more detail below, regulate hemopoiesis not only in vitro but 
also in vivo (Donahue et al, 1986), indicating that also in vivo stem cells can respond 
to specific hormonal signals. 
1.1.3. In vitro clonogenic assays 
The identification of the hemopoietic progenitor cells still depends on in vitro 
clonogenic assays developed more than twenty years ago. Pluznik and Sachs (1966) 
and Bradley and Metcalf (1966) discovered independently that suspensions of 
individual cells from mouse bone marrow could be induced to form colonies of 
mature granulocytes and macrophages. Each of the colonies consists of one cell clone. 
In 1970 Pike and Robinson adapted this culture system for the use of human marrow 
cells. Whereas at first only the growth of granulocyte-macrophage colonies could be 
induced, improvement of the colony culture system made it possible to grow erythroid 
and mixed colonies as well. The cell producing a colony is called a colony forming 
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unit (CFU). The most primitive in vitro colony forming cell is the CFU-blast (Naka-
hata and Ogawa 1982; Suda et al., 1983), which appears to be more primitive than the 
CFU-GEMM, a pluripotent cell rendering mixed granulocyte-erythrocyte-macrophage-
megakaryocyte colonies (Johnson and Metcalf, 1977; Hara et al., 1981; Fauser et al., 
1979; Johnson et al, 1980). Recently, using a miniaturized stroma-dependent bone 
marrow culture assay, various progenitor cell types have been identified in the mouse, 
which are more primitive than the CFU-GEMM and the CFU-blast. This cobblestone 
area-forming cell (CAFC) includes primitive precursor cells resposible for long term 
in vivo repopulation of a depleted hemopoietic system (Ploemacher et al, 1989). The 
progeny of the CFU-GEMM, the committed progenitor cells produce either granulo-
cyte-macrophage colonies (CFU-GM) (Bradley and Metcalf, 1966; Ichikawa et al., 
1966; Pike et al., 1970), or colonies of only neutrophilic granulocytes (CFU-G), 
macrophages (CFU-M), eosinophils (CFU-Eo) (Chervenick et al., 1971; Johnson and 
Metcalf, 1980), erythroid cells (BFU-E and more mature CFU-E) (Stephenson et al., 
1971; Axelrad et al., 1973; Tepperman et al., 1974) or megakaryocytes (CFU-Meg) 
(Metcalf et al., 1975; Vainchenker et al., 1979) (Fig.1). In most of the culture systems 
feeder layers were included with leucocytes or cells from an in vitro established cell 
line. Later it was found that the conditioned medium of the feeder cells contained 
substances capable to induce colony growth. These substances have become known as 
the colony stimulating factors. 
1.1.4. In vitro clonogenic assays in acute myeloblastic leukemia 
Shortly after the development of culture techniques for normal hemopoietic 
progenitor cells these methods were applied in acute myeloblastic leukemias 
(Robinson et al., 1971; Moore et al., 1973 and 1974). It was found that despite the 
apparent homogeneity of most populations of acute myelogenous leukemia (AML) 
cells, only a small fraction of cells had the capacity to proliferate in vitro. These 
clonogenic leukemic cells possibly act as stem cells in vivo to maintain the rest of the 
leukemic cell population. The normal clonogenic assays were often found to be 
insufficient to induce the formation of AML colonies. The growth of AML clonogenic 
cells in vitro is characterized by micro- (less than 20 cells) and macro-cluster (20 - 40 
cells) formation with defective maturation or persistent blasts within the clusters, a 
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high cluster colony ratio, singly persisting blasts, or a very low colony formation ( <2 
colonies/105 marrow cells) (Moore et al., 1974). It was concluded that specific 
clonogenic assays were required to induce more efficient AML colony growth. 
Exposure of the cells to phytohemaglutinin (PHA) during a 15-hour preincubation in 
suspension and subsequent culture in soft agar with a leukocyte feeder resulted in the 
formation of significant numbers of AML clonies of more than 50 cells in the majority 
of AML patients (Dicke et al., 1976). 
In subsequent modifications of the technique, PHA was added directly to cultures 
containing irradiated leukocytes or cell-line conditioned medium in the agar under-
layer and the AML target cells in a liquid overlayer (LOwenberg and Hagemeijer, 
1977 and 1980, Schipperus et al., 1988). In these modified cultures it was possible to 
induce AML colony formation in 80-90% of cases (Swart et al., 1982). The colonies 
are composed of morphologically identifiable blast cells carrying abberant karyotypes, 
typical for the AML clone (LOwenberg and Hagemeijer, 1977 and 1980). 
1.1.5. Immunological phenotype of clonogenic cells 
Hemopoietic cells express many glycoproteins on their surface membrane. Monoclo-
nal antibodies (McAbs) have been raised against many of these glycoprotein antigens. 
Expression of a set of antigens designates a cell to a particular differentiation stage 
and McAbs can be used for the identification of the cells wich express the antigens. 
In order to classify the large number of McAbs against immunologic markers, an 
international nomenclature has been developed (Bernard et al., 1984; Reinherz et al., 
1986; McMichael et al., 1987; Knapp et al., 1989). The various McAbs (and the 
recognized immunologic markers) are classified in clusters of differentiation (CD). 
Recently, considerable progress has been made in the identification of normal 
progenitor cell surface antigens, and different stages of normal progenitor cells can 
now be recognized by their immunological phenotypes. CFU-GEMMs express HLA-
DR, CD33 and CD34. The CFU-GM, CFU-G, CFU-M express CD13, CD15, 
CDw17, CD31, CDw32, CD33 and CD34 (Van Dongen et al., 1987; Vander Schoot 
et al., 1989). Studies on the phenotype of the AML-clonogenic cell (AML-CFU) 
revealed data suggesting that AML-CFU phenotypes vary among different patients. 
About 1/3 of cases showed phenotypes comparable to CFU-GEMM (or more 
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primitive) cells, while the other 2/3 expressed phenotypes of committed progenitor 
cells (Griffin et al., 1986) and therefore representing the neoplastic counterpart of 
different normal bone marrow progenitor cells. The double expression by one cell of 
antigens for different lineages can be used as a tumor marker (Smith et al., 1983), 
although in normal hemopoiesis such double positive cells can also arise in extremely 
low numbers. Terminal deoxynucleotidyl transferase (TdT) is found on the nuclear 
membrane of normal precursor B and T cells as well as of their malignant counter-
parts (i.e. acute lymphoblastic leukemia and some malignant lymphoma cells). 
However in a majority of AML cases also a subpopulation of the leukemic cells are 
TdT positive (Bradstock et al., 1981; Jani et al., 1983; Adriaansen et al., 1990). These 
TdT-positive AML cells may be used to monitor the disease and to detect minimal 
residual disease (MRD). 
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1.2. THE HEMOPOIETIC COLONY STIMULATING FACTORS 
1.2.1. The effect of colony stimulating factors on progenitor cells 
The development of semisolid culture systems necessary to grow bone marrow cells in 
vitro led to the identification of hemopoietic growth factors (HGF) or hemopoietins; 
of these erythropoietin (Epo ), granulocyte-macrophage colony-stimulating factor 
(GM-CSF), granulocyte colony-stimulating factor (G-CSF), macrophage colony 
stimulating factor (M-CSF), and interleukin-3 (ll-3) have been purified and cloned. At 
present they can be produced on a large scale through recombinant DNA technology 
and their biological activities have subsequently been defined (Table 1). 
Erythropoietin was the first human hematopoietic growth factor to be identified. The 
renal origin of erythropoietin was demonstrated by Jacobson (1957). It was originally 
purified to homogeneity from human urine (Miyake, 1977), and a complementary 
DNA (eDNA) was later identified and brought to expression in mammalian cells 
(Jacobs et al., 1985; Lin et al., 1985; Browne et al., 1986). Erythropoietin stimulates 
the formation of CFU-E (Metcalf and Johnson, 1979), does not support the survival 
and/or proliferation of BFU-E or any other progenitor cell (Metcalf et al., 1980), 
although, some effect on the CFU-Meg is reported (Vainchenker et al., 1979; 
Kawakita et al., 1983; Dessypris et al., 1987; Ishibashi et al., 1987). 
Granulocyte colony-stimulating factor (G-CSF) and macrophage colony stimulating 
factor (M-CSF) are relatively lineage specific hemopoietins which directly support the 
proliferation of the CFU-G (Nagata et al., 1986; Souza et al., 1986) and CFU-M 
(Stanley and Guilbert, 1981) respectively. ll-3 and GM-CSF are multipotential 
hematopoietic growth factors with overlapping but distinct activities (Emerson et al., 
1988). ll-3, however, is more effective in stimulating early multipotential progenitors 
as the CPU-blast and the CFU-GEMM (Leary et al., 1987; Sonada et al., 1988). ll-3 
is reported to be more effective than other colony stimulating factors in stimulating 
long-term maintenance of progenitor cells in vitro (Kobayashi et al., 1989) and acts 
not by direct stimulation of stem cell self-renewal (Zipori and Lee, 1988) or by 
triggering early progenitor cells into active cell proliferation, but it is necessary for 
their continuance of proliferation (Suda et al., 1985). More recent studies indicate 
that ll-3 stimulates CFU-GEMM, BFU-E, and CFU-Eo directly, whereas the 
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Table 1. Biological actions of the colony stimulating factors. 
Growth 
Factor 
Il-3 
GM-CSF 
G-CSF 
M-CSF 
Epo 
Progenitor cell 
Target 
CPU-blast, CFU-GEMM, CFU-GM, 
CFU-G, CFU-M, CFU-Eo, CFU-Meg, 
CFU-Baso, BFU-E. 
CPU-Blast, CFU-GEMM, CFU-GM, 
CFU-G, CFU-M, CFU-Eo, CFU-Meg. 
CFU-G 
CFU-M 
CFU-E, late BFU-e, CFU-Meg 
Mature-Cell 
Target 
Eosinophils, 
Basophils, 
rnonocytes 
Granulocytes, 
Eosinophils, 
rnonocytes 
Basophils 
Granulocytes, 
Monocytesj-
Macrophages 
None 
stimulation of CFU-GM, CFU-G and CFU-M requires the presence of monocytes or 
the addition of GM-CSF (Bot et al., 1989). This suggests that some of the effects of 
IL-3 are mediated by GM-CSF, produced by accessory cells. Similarly, G-CSF and M-
CSF can synergize with GM-CSF in the stimulation of CFU-G and CFU-M respec-
tively (Caracciolo et aL, 1987; Leary et al., 1987; Sonada et al., 1988; Ferrero et al., 
1989; Namiki and Hara, 1989). These observations are in accordance with the 
hypothesis of a hierarchy of colony-stimulating factors in hemopoietic development, 
with the sequence: ll-3, GM-CSF followed by G-CSF, M-CSF or Epo (Metcalf, 1984). 
1.2.2. The related interleukins 
Most of the interleukins act on lymphoid cells, but some also stimulate, either directly 
or indirectly, the proliferation and differentiation of other cell types. Il-l (a and 13) 
has been shown to regulate the cell growth of fibroblasts (Dukovich et al., 1986), 
epithelial cells, hemopoietic cells (Sieff et al., 1987, Broudy et al., 1987; Bagby et al., 
1986) and lymphoid cells (Tartakovsky et al., 1988; Jelinek et al., 1987; Freedman et 
al., 1988). Il-2 is a growth and differentiation factor for T-cells (Robb, 1984), Il-4 for 
resting B-cells (Sanderson et al., 1986), Il-5 for activated B-cells and a growth and 
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differentiation factor for eosinophils (Kinashi et al., 1986). Interleukin-6 has been 
reported to be involved in the induction of immunoglobulin production in activated B 
cells (Hirano et al., 1985, 1986), induction of 11-2 production, cell growth, and 
cytotoxic T-cell differentiation of T-cells (Garman et al., 1987, Okado et al., 1988), 
induction of proliferation of hybridomajplasmacytomamyeloma cells (Van Snick et 
al., 1986, 1987; Nordan and Potter 1986; VanDamme et al., 1987; Kawano et al., 
1988), stimulation of colony formation of multipotential hemopoietic cells (Ikebuchi 
et al., 1987), regulation of acute phase response (Andus et al., 1987) and induction of 
neural differentiation (Satoh et al., 1988). 11-7 is active on immature B cells (Namen 
et al., 1988). IL-8 is a neutrophil chemotactic factor (Yoshimura et al., 1987; Mat-
sushima et al., 1988). The two most recently defined growth factors are ll-9, which 
stimules erythroid colony formation in vitro (Y and et al., 1989; Donahue et al., 1989) 
and ll-10, which is an inhibitor of cytokine synthesis (Moore et al., 1990). 
1.2.3. The effect of colony stimulating factors on mature cells 
In addition to the effect on progenitor cell proliferation and differentiation, hemopo-
ietic growth factors may act on mature blood cells (Table 1). GM-CSF and G-CSF 
sustain the viability of neutrophils. They enhance their ability to produce superoxide 
anions in response to the bacterial peptide f-Met-Leu-Phe, to kill tumor targets 
through antibody-dependent cellular cytotoxity, and to phagocytize particles (Platzer 
et al., 1985; Lopez et al., 1986; Klausmann et al., 1988). GM-CSF also regulates the 
survival and function of eosinophils and macrophages and it is a potent inhibitor of 
neutrophil migration (Vadas et al., 1983; Gasson et al., 1984; Lopez et al., 1986; 
Metcalf et al., 1986; Silberstein et al., 1986; Arnaout et al., 1986; Socinski et al.,1988). 
M-CSF increases the tumoricidal activity of monocytes (Mufson and Ahgajanian, 
1987). 11-3 can act as a functional regulator of mature eosinophils, and monocytes 
(Cannistra et al., 1988; Rothenberg et al., 1988), and is reported to induce basophil 
histamine release (Haak-Frendscho et al., 1988). 
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1.2.4. The effect of colony stimulating factors on leukemic and non-hemopoietic cells 
Apart from their effect on normal hemopoietic cells the colony-stimulating factors are 
able to stimulate the proliferation of myeloid and erythroid leukemic cell lines and of 
myeloid leukemia blast cells in vitro. GM-CSF, G-CSF and Il-3, but less frequently 
M-CSF, stimulate AML growth in vitro (Hoang et al., 1986; Delwel et al., 1987; 
Griffin et al., 1986b; Mitjavila et al., 1987; Vellenga et al., 1987; Delwel et al., 1988). 
The response pattern of cells of different AML cases have been shown to be 
heterogeneous. Probably different subsets of cells exist in AML with distinct abilities 
to respond to CSFs (Delwel et al., 1988). Differentiation induction of leukemic blast 
cells, especially by G-CSF, has also been reported (Souza et al., 1986; Miyauchi et al., 
1988). More recently the hemopoietic growth factors have been reported to act also 
on non-hemopoietic cells. For instance, they may induce human endothelial cells to 
migrate and proliferate (Bussolino et al, 1989), and may stimulate the growth and/ or 
differentiation of non-hemopoietic tumor cell lines (Ruff et al., 1986; Baldwin et al., 
1989; Berdel et al., 1989). 
1.2.5. The production of colony stimulating factors. 
The colony stimulating factors can be produced by a variety of cells (table 2); Il-3 and 
GM-CSF by activated T-cells and monocytes (Wong et al., 1985; Otsuka et al., 1988; 
Sieff et al., 1988; Ernst et al., 1989), whereas fibroblasts, monocytes and endothelial 
cells can be induced to synthesize GM-CSF and G-CSF (Bagby et al., 1986; Horiguchi 
et al., 1987; Oster et al., 1987; Yang et al., 1988a; Kaushansky et al., 1988; Vellenga 
et al., 1988). Fibroblasts and endothelial cells appear to synthesize M-CSF constituti-
vely (Sieff et al., 1988). Only erythropoietin and M-CSF are present in the serum in 
biologically active concentrations (Garcia et al., 1982; Das et al., 1981; Hanamura et 
al., 1988). G-CSF can be detected transiently following intensive chemotherapy or in 
disorders associated with neutropenia and in approximately 10% of normal sera 
(Watari et al., 1989). Il-3 and GM-CSF are not detectable as a circulating molecule. 
These growth factors seem to act locally in a paracrine fashion. In this respect it is of 
interesst that GM-CSF has been reported to become compartmentalized in the 
extracellular matrix of the bone marrow stroma (Gordon et al., 1987; Roberts et al., 
1988). 
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Figure 2. Cytokine cascades involving macrophage production of IL-l, interactions with T 
cells and stromal cells, and the production of different colony stimulating factors and 
interleukins that influence bone marrow progenitor cell proliferation and differentiation. 
According to Moore MAS. Role of interleukin-1 in hemopoiesis. Immunol Res 1989; 8: 
165. 
1.2.6. Synergistic and additive effects between colony stimulating factors. 
Synergism with hemopoietic growth factors was first described by Stanley et al. (1986) 
for an activity called hemopoietin-!. Hemopoietin-1 has now been demonstrated to be 
ll-1 (Mochizuki et al., 1987). It has been shown that ll-1 produced in response to 
inflammatory stress can stimulate the proliferation and differentiation of myeloid 
progenitor cells. ll-1 is a potential stimulator of the production of G-CSF and GM-
CSF by endothelial, stromal and fibroblast cells, of G-CSF, GM-CSF and gamma-
interferon by macrophages, and ll-3 and GM-CSF by T cells (Bagby et al., 1986; 
Bagby, 1987; Sieff, 1987; Broudy et al., 1987; Fibbe et al., 1988) (Fig.2). Furthermore 
it has been demonstrated that the expression of the genes for G-CSF, GM-CSF, ll-6 
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Figure 3. Growth factor dependence in the neutrophil lineage, depicting the target cells for 
competence, progression and differentiation factors. IL = interleukin; CSF = colony-
stimulating factor. (Ikebuchi et al. 1985; Caracciolo et al. 1989). 
and Il-l itself can be induced by Il-l (Zsebo et al., 1988; Broudy et al., 1987; Sieff et 
al., 1988; Lee et al., 1987; Kaushansky et al., 1988). 
Vice versa, the CSFs are able to induce the elaboration of cytokines, e.g. Il-l by 
granulocytes (Lindemann et al., 1988) and mononuclear cells (Sisson and Dinarello, 
1988), whereas ll-3 and GM-CSF recruit monocytes to express and secrete G-CSF 
(Oster et al., 1989). 
The action-mechanism of these synergistic effects has not been elucidated yet. One 
hypothesis postulates that Il-l induces the expression of hemopoietic growth factor 
receptors on progenitor cells (Stanley et al., 1986), suggesting a direct effect of Il-l on 
progenitor and stem cells. Another possibility is that Il-l recruits quiescent progenitor 
cells into cell cycle (Ikebuchi et al., 1987; Leary et al., 1988) resulting in a priming for 
the action of hemopoietic growth factors. More recently it has been postulated that Il-
l increases the stability of the mRNA of hemopoietic growth factors (Bagby, 1989) 
produced by accessory cells, suggesting that the effect of Il-l is indirect through 
augmenting growth factor production. The action of Il-l might be even more complex, 
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since it has been shown that some of the effects of Il-l are mediated by other factors, 
for instance Il-6 (Helle et al., 1988). All these data point to the existence of a 
cytokine network consisting of reciprocal induction of cytokines, transmodulation of 
cytokine cell surface receptors and synergistic, or additive interactions with cell 
function. Theoretically the hemopoietic growth factors may be grouped on the basis 
of these functions. The competence factors prime progenitor cells to make them 
responsive or more responsive to the activities of other factors. Examples of such 
factors are Il-l and Il-6. Subsequently, a progression factor like Il-3 or GM-CSF 
provides the second signal, after which a lineage specific factor like G-CSF, M-CSF or 
Epo stimulates terminal differentiation and maturation of the hemopoietic cells. The 
role of G-CSF and Il-6 in this model is still somewhat controversial, since both 
cytokines enhance proliferation of primitive stem cells (Ikebuchi et al., 1987; Ikebuchi 
et al., 1988) and also induce differentiation of committed granulocYtic progenitor 
cells, (Caracciolo et al., 1989), acting therefore both as a competence and a differen-
tiation factor (Fig 3). 
1.2.7. Inhibitory effects of cytokines. 
All the cytokines described above have growth factor activity. The ability to inhibit 
cell growth or directly kill cells is limited to T-interferon (IFNT) (Raefsky et al., 1985: 
Mamus et al., 1985), tumor necrosis factor (TNF) (Degliantoni et al., 1985; Brox-
meyer et al., 1986), lymphotoxin (LT) (Murphy et al., 1986), and transforming growth 
factor 13 (TGF13) (Espevik et al., 1987; Hino et al., 1988). It was recently appreciated 
that some of the cytokines ( TNFa) (Ishikura et al., 1989), Il-l (Santoli et al., 1987; 
Gasparetto et al., 1989) and Il-4 (Rennick et al., 1987) may act as a stimulator in one 
context, but as an inhibitor in another. This dual action depends either on the 
presence of other cytokines and the differentiation stage of the target cell or their 
concentration. Evidence of antagonistic competition between CSFs has been docu-
mented by Metcalf (1988). When M-CSF and G-CSF act in combination on bipoten-
tial progenitor cells there appears to be an element of competition in the commit-
ment to the formation of granulocytic or macrophage progeny. However, if G-CSF is 
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Table 2. Main characteristics of the hemopoietic growth factors. 
Factor Molecular Chromosomal Cellular 
Mass (kD) location sources 
Il-3 14-28 5g23-31 T-cells, monocytes 
GM-CSF 14-35 5g21-32 T-cells, monocytes, 
fibroblasts, 
endothelial cells 
macrophages 
G-CSF 18-22 17q11.2-q21 Monocytes, fibroblasts, 
endothelial cells. 
M-CSF 40-90(dimer) 5g33.1 Monocytes, fibroblasts, 
Endothelial cells. 
Il-laj,B 17.5 2g12-21 Monocytesjmacrophages, 
Fibroblasts, 
Endothelial cells, 
Smooth muscle cells 
Il-6 26 7p21 Fibroblasts, monocytes, 
T-cells 
Epo 34-39 7qll-22 Peri tubular cells of the 
kidney, Kupffer cells. 
combined with low concentrations of M-CSF, there is also enhancement of the 
number and size of granulocytic colonies, demonstrating a delicate balance between 
antagonism and enhancement. 
1.2.8. Biochemistry of the colony stimulating factors. 
The CSF's are low molecular weight proteins ( < 80 KDa), which are variably 
glycosylated. Therefore each natural CSF occurs in different molecular weight forms 
(Clark and Kamen 1987; Sieff et al., 1988) (table 2). For the function of most of the 
hemopoietic growth factors glycosylation is not essential, but it has been reported that 
glycosylated GM-CSF is less active in vitro than non-glycosylated GM-CSF (Moonen 
et al., 1987). Moreover, the biological activity of erythropoietin in vivo is dependent 
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on proper glycosylation (Browne et al., 1986). The presence of cysteine residues 
suggests that disulphide bonds may be structural features of the molecules. The CSF's 
contain at least four cysteine residues, except Il-3 which contains only two cysteines 
(Yang et al., 1986). There is no significant sequence homology among these proteins. 
However, Il-6 was recently reported to show homology with G-CSF in a specific 
region where four cysteine residues reside. Moreover, the genes of both Il-6 and G-
CSF, consisting of four introns and five exons, exhibit similar genomic organization 
(Hirano et al., 1986). Il-l has two structurally different forms, a and B, which are 
products of separate genes on chromosome 2 (Modi et al., 1988). Il-18 is the predo-
minantly secreted form, and Il-1a is predominantly membrane bound. Both Il-la and 
B bind to the same receptor (Oppenheim et al., 1986). 
It is interesting that in man the genes for Il-3, Il-4, Il-5, GM-CSF, and M-CSF are 
clustered in the same band on the long arm of chromosome 5 (Yang et al., 1988b; 
Wong et al., 1985; Pettenati et al., 1987) (table 2). This region has also been shown to 
contain the proto-oncogen c-fms, encoding the M-CSF receptor , the gene for the en-
dothelial cell growth factor (ECGF) and the gene for the platelet derived growth 
factor (PDGF) receptor (Le Beau et al., 1986; Sherr et al., 1985). This is especially 
intriguing since deletions of the long arm of chromosome 5 (5q-) are frequently 
observed in patients with a myelodysplastic syndrome or acute myeloid leukemia 
secondary to chemotherapy. The gene for G-CSF has been localized on chromosome 
17 (Simmers et al., 1987), whereas the erythropoietin (Law et al., 1986) and Il-6 
(Bowcock et al., 1988) gene are being mapped on chromosome 7. 
The CSFs have high specific biological activity, stimulating cell proliferation in the 
1010 - 1012 M range. Their effects are mediated through a limited number (only a few 
hundred for each type of CSF) of specific receptors present on cell membranes, yet 
signalling is achieved by CSFs with low receptor occupancy (Park et al., 1986; Gasson 
et al., 1986; Dipersio et al., 1988). The receptors comprise an extracellular, transmem-
brane and intracellular domain. Their binding leads to changes in the intracytoplas-
matic domain and activation of a cascade of biochemical responses eventually 
resulting in stimulation of DNA synthesis. A description of this cascade of responses 
lies beyond the scope of this thesis. 
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1.3. THE MYELODYSPLASTIC SYNDROMES 
1.3.1. History 
The current concept of the myelodysplastic syndrome (MDS) emerges from studies on 
apparently two different diseases ; refractory anaemia on the one hand and preleuke-
mia on the other. The refractory anemias were recognized in the 1930's, when it 
became apparent that these anemias were refractory to treatment with all known 
hematinics. In addition no specific metabolic defects could be identified. Roads and 
Halsey Barker (1938) described 100 cases of refractory anemia, which was often 
associated with leukopenia and trombocytopenia. 
The observation that acute myeloid leukemia can be preceded by a refractory anemia 
with also dysplastic features of the bone marrow, was first made at the beginning of 
this century (Von Leube, 1900; Parkes-Weber, 1904). Hamilton-Paterson (1949) 
described three patients who presented with refractory anemia and subsequently 
developed an acute myeloid leukemia, indicating that at least some of the refractory 
anemias should be considered to be preleukemic. The term 'preleukemia' was 
introduced by Block et al. in 1953, who observed 12 patients for as long as 27 months 
prior to the development of acute myelogenous leukemia. In the following years 
apparently similar conditions were described (Meacham and Weisberger, 1954; 
Bjorkman, 1956). Prospective studies performed more recently show an evolution 
pattern from normal hemopoiesis through a clinically recognizable dysplastic syn-
drome to overt leukemia (Nowell et al., 1986; Todd and Pierre, 1986). Dameshek 
(1965) was the first to link the refractory anemias to the Di-Guglielmo's erythro-
leukemia. He proposed that the two were different phases of the same disease and 
called it the Di-Guglielmo's syndrome. At about the same time a distinct group of 
refractory anemias was recognized having a prominent population of bone-marrow 
erythroblasts with perinuclear iron deposits or siderotic granules, the ringed sidero-
blasts. This subgroup presently known as the acquired idiopathic sideroblastic anemia 
(AISA) (Bjorkman, 1956), is usually characterised by a insidious clinical course (Beris 
et al., 1983). Saarni and Linman (1973) and later Linman and Bagby (1978) develo-
ped the concept of 'the preleukemic syndrome', defined by dysplastic features of the 
megakaryocytes and granulocytes as well as dyserythropoiesis, with no more than 5% 
blast cells detectable in the bone marrow. Concurrently Dreyfus et al (1970) and 
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Dreyfus (1976) described patients with 'refractory anemia with excess of myeloblasts' 
with identical morphological abnormalities as noted by Linman. In 1982 the French-
American-British (FAB) co-operative group (Bennett et al., 1982) proposed the 
unifying concept of the myelodysplastic syndrome, subdivided in five separate entities: 
1. refractory anemia (RA); 
2. refractory anemia with ring sideroblasts (RARS) 
3. refractory anemia with excess of blasts (RAEB); 
4. chronic myelomonocytic leukemia (CMML). 
5. refractory anemia with excess of blasts in transformation (RAEBt). 
These different groups of the F AB classification are described in more detail below. 
With cytogenetic analysis of the bone marrow cells and glucose-6-phosphate dehydro-
genase isoenzyme studies in female heterozygotes it was possible to demonstrate that 
MDS is a clonal disease of the pluripotent hemopoietic stem cell (Fialkow et al., 
1981; Raskind et al., 1984). Disease progression in MDS may be due to the gradual 
clonal expansion of the abnormal population with suppression of the normal hemopo-
iesis (Abkovitch et al., 1984). More recent reports, presenting data on X-linked 
restriction fragment length polymorphism, provide evidence that MDS is a clonal 
disorder of the pluripotent stem cell, which clone has totally replaced the normal 
hemopoiesis (Janssen et al., 1989; Tefferi et al., 1990). 
1.3.2. Morphological characteristics of the MDS 
In order to describe the morphological features underlying refractory anemia, Lewis 
and Verwilghen (1972) introduced the term "dyshematopoiesis". Dyshematopoiesis 
may be observed in one or more hemopoietic cell lines (Table 3): 
Dyserythropoiesis: 
The presence of ringed sideroblasts, multinuclearity, nuclear fragments, Howell-Jolly 
bodies and nuclear-cytoplasmic asynchrony with intense cytoplasmic basophilia are 
morphological features in the bone marrow. In the peripheral blood basophilic 
stippling and fragmentation of the erythrocytes with moderate anisocytosis and 
poikilocytosis are usually seen. 
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Table 3.Qualitative abnormalities in the myelodysplastic 
syndromes 
Cell lineage 
Erythroid 
Peripheral blood 
Macrocytes; dimorphic 
picture; anisopoikilo-
cytosis 
polychromatic cells; 
normoblasts (often dys-
erythropoietic) 
Bone marrow 
Erythroid hyperplasia 
ring sideroblasts 
dyserythropoisis 
Megaloblasts 
Cytoplasmic vacuo 
lization 
Megakaryocytic Giant platelets; 
megakaryocyte fragments 
Small megakaryocytes 
with one or two small 
round nuclei; larger 
forms with single large 
ovoid nucleus; 
polynuclear forms 
Granulocytic 
Monocytic 
Blasts 
Dysgranulopoiesis: 
Hypo- or agranular 
neutrophils; speudo-
pelger-Huet neutrophils 
Mature forms sometimes 
with multiple elongated 
lobes, some with fine 
azurophilic granules 
Promyelocytes with 
sparse azurophilic 
hypo- or agranularity 
of myelocytes, meta-
myelocytes and 
neutrophils 
Promonocytes 
sometimes present 
Usually small mononuclear blasts with scanty 
agranular (type I) or sparsely granular (type II) 
blasts. 
This is characterized by hypogranulation and hyposegementation of the granulocytic 
cells. Excessive chromatin condensation (pseudo-Pelger-Huet anomaly), but also 
hypersegmentation with unequally sized lobes can be seen. Additionally persistent 
basophilia and excess azurophilic of the promyelocytes may be prominent in the bone 
marrow. 
Dysmegakacyocytopoiesis: 
Micromegakaryocytes, multiple small hypersegmented nuclei and large mononuclear 
forms are typical features of the bone marrow. The platelet production may appear 
normal, increased or decreased. In the peripheral blood abnormal platelets, especially 
giant forms are often present. 
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1.3.3. Classification 
Although the FAB entities are defined by arbitrary criteria (Table 4), it is usually 
possible to classify them according to the following crititeria: 
1. Refractozy anemia (RA) 
The anemia is frequently accompanied by some neutropenia and trombocytopenia. 
The peripheral blood containes less than 1% blast cells and the bone marrow less 
than 5%. The bone marrow is normo- to hypercellular. Erythroid hyperplasia with 
dyserythropoiesis is a common feature. Some degree of dysgranulopoiesis or dys-
megakaryopoiesis may be present. 
2. Refractozy anemia with ringed sideroblasts (RARS) (acquired idiopatic sideroblas-
tic anemia. AISA): 
The morphological features resemble those of RA, but dysgranulopoiesis and 
dysmegakaryopoiesis are not as common. The major marrow characteristic is a high 
number of ringed sideroblast of at least 15% of the nucleated cells. 
3. Refractozy anemia with excess of blasts (RAEB): 
Some degree of peripheral cytopenia is usually seen in all three lineages. Dyseryth-
ropoiesis as well as prominent dysgranulopoiesis are present. Blast counts may 
amount to 5% in the peripheral blood and to 5- 20% in the bone marrow. The bone 
marrow is normocellular and or often hypercellular, with erythroid and myeloid 
hyperplasia. 
4. Chronic myelomonocytic leukemia (CMML): 
The major feature of CMML is the presence of monocytosis in the peripheral blood 
and the bone marrow. The minimal number of peripheral monocytes required for this 
MDS entity is 1 x 10 9/1. The morphological features of the bone-marrow resemble 
RAEB in some cases and RA in others. 
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5. RAEB in transformation (RAEBt): 
This MDS category fills in the the gap between RAEB and AML. Bone marrow blast 
counts amount from 20- 30% and more than 5% circulating blast cells may be 
present. Auer rods are seen occasionally. 
Table 4.Classification of the myelodysplastic syndrome 
FAB 
type 
Refractory 
anemia (RA) 
RA with ring-
sideroblasts 
(RARS) 
RA with excess 
of blasts 
(RAEB) 
RAEB in trans-
formation 
(RAEBt) 
Chronic myelo-
monocytic leukemia 
(CMML) 
1.3.4. Clinical features 
Peripheral 
blood 
< 1% blasts 
< 1% blasts 
< 5% blasts 
< 5% blasts 
± Auer rods 
< 5% blasts 
> 1 X 109/1 
monocytes 
Bone marrow 
Dyshemopoiesis in one 
or more lineages 
< 5% blasts 
As RA with >15% ring-
sideroblasts 
As RA with 5-20% blasts 
As RA with 20-30% blasts 
± Auer rods 
As any of the above 
+ promonocytes 
Usually the patients with a myelodysplastic syndrome are older than 50 years. Most 
patients present with anemia. Infections or sometimes bleeding may also be the first 
symptoms. Infection are usually bacterial, respiratory or septicemic. Splenomegaly 
occurs almost exclusively in CMML. 
The natural history of MDS is a transition to overt non-lymphocytic leukemia in 
approximately half of the patients. However, most patients die of the consequences of 
marrow failure, i.e., bleedings or infections. Three patterns of evolution based on 
sequential determinations of bone marrow blasts can be observed in MDS (Tricot et 
al., 1985 and as illustrated in figure 4: 1) an apparently stable disease with no or a 
minimal increase of bone marrow blasts 2) initially a morphologically stable disease, 
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diagnosis AML 
Figure 4. Hypothetical model of evolation patterns in patients with MDS. 1, stable clone, 
with low proliferative capacities; 2, stable clone, with a more pronounced proliferative 
capacities; 3, instable clone, with initially a stable disease, but with a high probability of 
transformation to a clone with a high proliferative capacity. Adapted from Tricot G, et al. 
1985. 
comparable with pattern 1, but changing into a progressive disease with a rapid 
increase in blast cells and a rapid transformation to acute leukemia and 3) with a 
gradual increase in bone marrow blasts. The majority of these patients eventually 
developed overt myeloid leukemia. 
1.3.5. Cytogenetics 
Karyotypic abnormalities have been detected in 40-60% of the MDS patients using 
conventional cytogenetic banding techniques (Jacobs et al., 1986; SIWCL, 1981). 
Refined high-resolution chromosome analysis has resulted in the detection of non-
random cytogenetic abnormalities in 79% of the MDS cases (Yunis et al., 1986; Yunis 
et al., 1988). The commonest abnormalities in MDS are deletions, rather than 
reciprocal translocations or inversions. Chromosomal deletions, such as monosomy 5 
(-5), 5q-, monosomy 7 (-7), 7q-, -Y, 20q- or trisomy 8 ( +8) or complex defects, often 
including one or more of the above abnormalities mentioned; represent the main 
chromosomal abnormalities in MDS . These are, however, not specific for MDS 
because they may also be seen in AML. There is also no apparent correlation 
between a particular chromosomal abnormality and any of the F AB subtypes of MDS 
(Knapp et al., 1985; Yunis et al., 1986; Yunis et al., 1988). However, the deletion of 
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the long arm of chromosome 5 (Sq-), when present as a sole defect, is associated with 
RA or RAEB, female sex, macrocytic anemia, normal or raised platelet counts, and 
erythroid hyperplasia with mononuclear megakaryocytes in the bone marrow 
(Kerkhofs et al., 1982; Van den Berghe, 1986). Monosomy 7 (-7) often goes with 
hypocellular marrow, pancytopenia and defective neutrophil functions (Pederson-
Bjergaard et al., 1982). The presence or absence of chromosomal abnormalities has 
prognostic significance. Certain chromosomal abberations are predictive for an 
unfavorable prognosis. The Sq- syndrome usually runs a benign clinical course, 
whereas -7, and 7q- is frequently associated with a rapid progresion and a high 
probability of leukemic transformation (Anderson and Bagby, 1982; Nowell et al., 
1986). The presence of complex cytogenetic abnormalities, an unfavorable prognostic 
feature, is often found in MDS cases secondary to chemotherapy. 
1.3.6. In vitro marrow cultures 
The use of in vitro clonogenic or colony assays has provided methods to analyze the 
hemopoietic progenitor compartments and the hemopoietic colony stimulating factors 
or cytokines involved in the regulation of cell proliferation and cell differentiation. As 
described above, it has been shown that MDS is a clonal disease of the hemopoietic 
stem cell and that the abnormal clone is already fully established in a relatively early 
stage of the disease. Moreover it was demonstated that both the BFU-E as well as 
the CFU-GM derived colony cells contain the same cytogenetic abnormality, indica-
ting that they stem from the same abnormal progenitor cell (Abkowitz et al., 1984). 
Therefore it appears to be likely that the in vitro growth characteristics of MDS bone 
marrow in clonogenic assays may reflect the functional abnormalities of the hemo-
poietic progenitor cells in MDS. 
The colony forming capacities of all different committed progenitor cells (CFU-
GEMM, BFU-E, CFU-E, CFU-GM, CFU-Meg) are usually decreased in MDS 
patients (Greenberg et al., 1983; Greenberg and Mara, 1979; Chiu and Clark, 1982; 
Juvonen et al., 1986; Swanson et al., 1986), as in AML patients. A defective matura-
tion of the colony cells is frequently observed (Golde and Cline, 1973; Spitzer et al., 
1979; Verma et al., 1979). Generally two growth patterns of the CFU-GM may be 
discerned: a 'leukemic' and a 'non-leukemic'type (Greenberg and Mara, 1979; Verma 
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et al., 1979; Spitzer et al., 1979; Gold et al., 1983). A non-leukemic type of growth is 
most frequently observed in the RARS (MDS 2) subgroup of MDS, which fits with 
the observation that RARS is less often accompanied by dysgranulopoiesis (Green-
berg and Mara, 1979; Greenberg, 1981). A leukemic type of growth is seen sometimes 
in RA, but most often in RAEB and RAEBt. In some cases of CMML the marrow 
culture shows growth of clusters as well as colonies as in CML. A leukemic growth 
pattern seems to be associated with a higher transformation rate to AML as com-
pared with a non-leukemic growth pattern (Verma et al., 1979). The erythroid burst 
and colony formation in MDS has been investigated less extensively. However, it has 
become evident that the formation of both BFU-E and CFU-E is defective in a 
majority of the MDS patients (Hutcheson et al., 1979; Chui and Clark, 1982; Amato 
and Khan, 1983; Ruutu et al., 1984). Information on the growth of megakaryocyte 
colonies is even more limited. Juvonen et al. (1989) found a defective CFU-Meg and 
BFU-E growth in all 10 patients studied, but only four had abnormal CFU-GM 
growth. Also in long-term marrow cultures the hemopoiesis can rarely be sustained 
beyond 2-4 weeks, while the cells retain their dysplastic features (Bourbenyi et al., 
1987). Attempts to correlate the in vitro growth patterns with the F AB classification 
have rendered different results. Ruutu et al., (1984) reported a correlation between 
normal CFU-GM numbers and RARS, whereas May et al., (1985) found no cor-
relation between FAB type and colony growth pattern. Oscier et al. (1989) found sig-
nificantly higher CFU-GM numbers in CMML than in RAEB and RAEBt in a large 
series of MDS patients, low or absent BFU-E growth in the majority of the patients 
with RARS, CMML, RAEB and RAEBt, but normal growth in 10 of the 22 RA 
patients (Table 5). 
Table 5. In vitro colony formation in the myelodysplastic 
syndromes 
Type CFU GEMM CFU-GM BFU-E CFU-E CFU-Meg 
RA Nj~ Nj~ N/~ Nj~ N/~ 
RARS N N N N N 
RAEB ~ ~ ~ ~ ~ 
RAEBt ~ ~ ~ ~ ~ 
CMML Njt t ~ ~ 
N,normal; t, increased; ~, decreased numbers of colonies 
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The nature of the defect leading to abnormal in vitro colony formation of the 
hemopoietic progenitor cells in MDS is not known. The abnormalities may be either 
an intrinsic progenitor cell defect, i.e. abnormal growth factor responsiveness, or an 
environmental one, i.e an abnormal growth factor production. The results obtained 
with in vitro bone marrow cultures, described above, are not capable to discriminate 
between these two possibilities, since the marrow cells are not fractionated and 
therefore contain many accessory cells, which can produce hemopoietic growth 
factors. Furthermore, all these studies were performed with crude sources of colony 
stimulating activity. Recently some results have been reported on the response to 
recombinant hemopoietic growth factors by purified MDS progenitor cells (Carlo-
Stella et al., 1989; Schouten et al., 1989), suggesting the presence of an intrinsic 
progenitor cell abnormality. However, also growth factor production abnormalities by 
bone marrow accessory cells was recently reported (Merchav et al., 1989). 
1.3.7. Prognostic factors 
Prognosis in MDS is extremely variable. The F AB classification has some prognostic 
significance, with a better prognosis for RA and RARS than RAEB and RAEBt. The 
most important factor in prognosis is the number of blast cells in blood and bone-
marrow. (Kerkhofs et al., 1986). The Boumemouth score (Mufti et al., 1985) allocates 
one point for each of the following features: an Hb concentration < 100g/l, for 
neutrophil count <2.5 x 109/1 or > 15 x 109 in CMML, for a platelet count < 100 x 
109 and for a bone marrow blast count > 5%. Patients with a score of 0 or 1 have 
the best prognosis with a median survival of 62 months; patients with a score of 2 or 
3 have a median survival of 22 months and patients with a score of 4 have a poor 
prognosis with a median survival of 8 months. A further prognostic factor has been 
described by Tricot et al., (1984). He designated clusters of myeloblasts abnormally 
localized in the central marrow as ALIPs (abnormal localization of immature 
precursors). ALIPs seen in some cases of RA are a independent indicator of a poor 
prognosis. The importance of karyotype and of the growth pattern of in vitro cultured 
bone marrow cells for prognosis are described above. 
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1.3.8. Treatment 
Since MDS patients are usually elderly, often only symptomatic treatment can be 
aplied. Intensive chemotherapy is eligible in patients not older than 50, in which a 
complete remission rate of 86% can be achieved with conventional chemotherapy 
(anthracycline and cytosine arabinoside (ARA-C)) or high dose ARA-C (Tricot et al., 
1986). In younger patients (<50 years), with HLA-compatible siblings, results of 
bone-marrow transplatation are encouraging and should be seriously considered as 
the treatment of choice (Appelbaum et al., 1987; Baines et al., 1988). In older 
patients some favourable results with low-dose ARA-C have been reported 
(Chomienne et al., 1987). MDS patients have been treated with G-CSF and GM-CSF 
(Vadhan-Raj et al.,1987; Antin et al., 1988; Ganser et al., 1989; Negrin et al., 1989). 
The majority of these patients have shown marked improvement of blood neutrophil 
counts after G-CSF and GM-CSF treatment but without improvement in platalet 
counts. In a low proportion of patients improved reticulocyte and hemoglobin levels 
occurred. Marrow myeloid maturation was better enhanced by G-CSF than by GM-
CSF. Caution must be taken with CSF treatment because there is a possibility of 
accelerating the proliferation of the leukemic clones. However, several investigators 
recently demontrated that treatment with GM-CSF altered cell growth kinetics 
(Herrmann et al., 1989) sensitizing leukemic blasts to cytotoxic drugs as shown by 
enhanced cell-kill in vitro. Studies of cell-kinetics and cytosine-arabinoside metabo-
lism proved that GM-CSF- induced recruitment of quiescent leukemic cells primed 
them to become more sensitive to cell-cycle specific cytotoxic drugs (Tafuri et al., 
1988; Cannistra SA et al., 1988; Andreeff M et al., 1989). Clinical trials with the 
combination of GM-CSF and ARA-C are presently performed in MDS. 
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1.4. INTRODUCTION TO THE EXPERIMENTAL WORK 
In this thesis studies were performed to characterize the abnormal hemopoiesis in 
MDS by using immunofluorescence analysis and in vitro colony assays in order to 
investigate the presence of intrinsic abnormalities of myelodysplastic progenitor cells, 
i.e. to detect immunophenotypicly abnormal subpopulations and abnormal respon-
siveness of progenitor cells to the various hemopoietic growth factors. 
In chapter 2, six patients with MDS (three with RARS, two with RAEB and one with 
RAEBt) were studied using double immunofluorescence analysis for the presence of 
terminal deoxynucleotidyl transferase (TdT) and myeloid-antigen (MM) expression. 
MM + /TdT + subpopulations occur in the majority of AMLs and these TdT-positive 
cells belong to the AML cell-population. The objectives of the experiments described 
in this chapter were to determine whether MM + /TdT + cells are detectable in MDS 
as well and TdT-positivity of myeloid cells is an useful marker for the abnormal 
granulopoiesis in MDS. 
In the following chapters the characteristics of colony formation by low-bouyant 
density bone marrow cells, depleted of T-cells and adherent cells, were studied. 
Colony growth patterns were studied in the PHA-clonogenic assay, which is also used 
for the growth of AML-CFU (Chapter 3). Subsequently the colony formation and 
growth kinetics of MDS bone marrow myeloid progenitor cells stimulated with 
recombinant 11-3, GM-CSF and G-CSF were studied and compared with the growth 
kinetics of normal myeloid progenitor cells and bone marrow cells cultured after 
exposure to 4-hydropero:xy-cyclophosphamide (4-HC)(Chapter 4). Primitive progenitor 
cells will be spared during in vitro 4-HC treatment. Therefore, 4-HC exposure will 
consequently result in a relative enrichement for early progenitor cells. Since the in 
vitro growth abnormalities of MDS bone marrow may be due to a relative left shift in 
the progenitor cell compartment, the objective of the 4-HC experiments was to 
compare the growth kinetics of MDS marrow with those of normal bone marrow 
relatively enriched for early progenitor cells. In these investigations a semi-solid 
colony assay was used in order to exclude possible cell-cell interactions and induce 
clonal growth of stem cell progeny. Since in vitro colony formation of MDS bone 
marrow stimulated with single CSF was found to be decreased, it was investigated 
whether combinations of 11-3, GM-CSF and G-CSF could enhance the growth of 
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MDS myeloid and erythroid progenitor cells, in other words, whether MDS progeni-
tors needed more CSFs for clonal expansion than their normal counterparts (Chapter 
5). Finally, the effects of competence factors such as IL-l and more extensively of Il-6 
on the GM-CSF induced colony formation of MDS and normal marrow cells were 
studied (Chapter 6). 
In chapter 7 the presented work is discussed in the context of the literature. 
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Abstract 
Six patients with a myelodysplastic syndrome (MDS) (three with refractory anemia 
with ringsideroblasts (RARS), two with RA with excess of blasts (RAEB) and one 
with RAEB in transformation (RAEBt)) were studied by double immunofluoresence 
(DIF) analysis for the presence of terminal desoxynucleotidyl transferase (TdT) and 
myeloid-antigen (MM), such as CD13, CD14, CD15 and CD33, expression. TdT 
expression was found in 0.1 - 11% of the cells. In four cases ( 1 RAEBt, 2 RAEB and 
1 RARS) 58 - 99% of the TdT+ cells expressed the panmyeloid markers CD13 
and/or CD33, whereas the precursor antigen CD34 was present in 26 - 99% of the 
TdT + cells. Follow up studies performed in two patients, that evolved into an acute 
myeloid leukemia (AML), showed in one patient an increase of MM+/TdT+ cells 
from 11% in RAEBt to 25% in AML-M2. In the other patient the percentage of 
MM + /TdT + cells was 0.1% at diagnosis, decreased during remission and increased 
to 0.2% before relapse RAEB and finally to 35% when AML-M2 emerged. These 
data indicate that the detection of MM + /TdT + cells in MDS may facilitate the 
detection of abnormal myeloid cells and may be useful to monitor these cells during 
disease progression. No MM + /TdT + cells were found in 2/3 RARS patients. In 
these two patients no features of dysgranulopoiesis were found. Moreover the latter 
two RARS cases had a low Boumemouth score, which indicates a good prognosis. In 
the other RARS patient 5% MM+/TdT+ cells were detected in parallel with 
dysgranulopoietic features and a high Boumemouth score, suggesting that DIF 
staining can discriminate between RARS cases with and without an abnormal 
granulopoiesis. 
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Introduction 
The enzyme terminal deoxynucleotidyl transferase (TdT) is expressed on the nuclear 
membrane of normal precursor B and T cells as well as their malignant counterparts, 
i.e., acute lymphoblastic leukemias and some lymphoblastic lymphomas (1,2). TdT 
positivity has also been found in acute myeloid leukemia (AML) (3,4,5). This has 
initially been ascribed to a 'mixed', 'biclonal' or 'biphenotypic' cell population in these 
leukemias (6). However, the simultaneous demonstration of TdT and Sudan black or 
myelo-peroxidase positivity in single blast cells proved the existence of 'TdT-positive 
leukemic myeloblasts' (4,7). Recently, we have demonstrated by double immunofluor-
escence (DIF) analysis that a TdT-myeloid-antigen double-positive (MM + /TdT +) 
leukemic subpopulation occurs in the majority of AMLs (8). 
The myelodysplastic syndrome (MDS) is a clonal disease of the hemopoietic stem cell 
characterized by an ineffective hemopoiesis resulting in a cytopenia of one or more 
cell lineages (9,10). The French-Americam-British (FAB) co-operative group has 
defined criteria for the classification of MDS (11), comprising 5 different entities, i.e., 
refractory anemia (RA), RA with ring-sideroblasts (RARS), RA with excess of blasts 
(RAEB), chronic myelomonocytic leukemia (CMML) and RAEB in transformation 
(RAEBt). Up to 40% of MDS cases evolve in an AML during the course of their 
disease (9). In MDS TdT-positivity has also been cited as an example of mixed-
lineage expression (12). However, no DIF analysis has been performed in these cases, 
and therefore the TdT-positive cells may belong to the myeloid differentiation 
lineage. We performed DIF analysis for TdT and differentiation markers for the 
myeloid and lymphoid lineage in six MDS patients (two with RARS, three with 
RAEB and one with RAEBt) in order to investigate the presence MM + /TdT + cells. 
In addition, we applied double marker analysis to monitor the MM + /TdT + sub-
population in two MDS patients during the course of their disease. 
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Patients and Methods 
Six patients with MDS were investigated; three females and three males, with a 
median age of 65 year (16-89 y). The clinical and hematological features of the 
patients are summarized in Table 1. Presenting symptoms were anemia in all cases, 
infection in two and bleeding in one. The diagnosis MDS was assessed according to 
the criteria, as defined by the FAB cooperative group (11,13,14), in films of peri-
pheral blood and bone-marrow stained with May-GrUnwald Giemsa. 
Prognostic scores were given to each patient according to the Bounemouth system 
(15), which allocates one point for each of the following features: an Hb of less than 
6.5 mmoljl, for a white blood cell-count of less than 2.5 x 109/1, for a platelet count 
of less than 100 x 109/1 and for a bone marrow blast count of more than 5%. Patients 
with a score of 0 or 1 have the best prognosis with a median survival of 62 months, 
patients with a score of 2 or 3 have a median survival of 22 months and patients with 
a score of 4 have a poor prognosis with a median survival of 8 months. 
Chromosomal analyses were performed at diagnosis and during the course of the 
disease according to a standard technique (16) and chromosomal abnormalities were 
described according to the ISCN (17). 
Immunological marker analyses were performed as described before (8). The 
expression of a series of immunological markers was tested, including terminal 
desoxynucleotidyl transferase (TdT), the B cell markers CD10 (VIL-A1; Dr. W. 
Knapp, Vienna, Austria) and CD19 (B4; Coulter Clone, Hialeah, FL, USA) the T-cell 
markers CD2 (Tll; Coulter Clone), CD3 (Leu-4; Becton Dickinson, San Jose, CA, 
USA) and CD7 (3A1; American Type Culture Collection, Rockville, MD, USA), the 
myeloid markers CD13 (My7; Coulter Clone), CD14 (My4; Coulter Clone), CD15 
(VIM-D5; Dr. W. Knapp) and CD33 (My9; Coulter Clone), the HLA-DR antigen 
(L243; Becton Dickinson), the precursor antigen CD34 (BI-3C5; Seralab, Crawley 
Down, UK) and glycophorin A (GpA) (VIE-G4; Dr. W. Knapp). The TdT-IF assay 
was performed by use of rabbit anti-TdT antiserum and a FITC-conjugated goat anti-
rabbit (Ig) antiserum (Supertechs, Bethesda, MD, U.S.A). DIF analysis for the 
differentiation markers CD2, CD7, CD10, CD19, CD13, CD14, CD15, CD33 and 
CD34 and for TdT were performed as described before (8). 
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Table 1 Features of patients with MDS at the time of diagnosis 
bone marrow peripheral blood bournemoU1h score 
sexjage Dx EB% MB% Hb mmol/1 ret% MCVfl WBC 10"9 Pl10"9 
1. M.M. M/17 RAEBt 62.4 8.8 4.1 40 100 2.9 14 3 
2. S.M. F/16 RAEB 47.6 7.2 3.9 24 111 3.0 36 3 
~ 3. J.N. F/87 RAEB 22.8 13.6 4.1 nd 95 1.6 52 4 
\0 
4. H.F. M/76 RARS 42.0 0.4 5.7 9 114 5.7 588 
5. H.B. F/65 RARS 57.6 1.2 5.7 10 112 4.8 345 
6. N.K. M/89 RARS 40.7 1.7 3.7 nd 89 1.9 59 3 
median 65 52.6 4.0 4.1 17 106 3.0 56 
Ox, diagnosis according to the FAB criteria; EB, erythroblasts; MB, myeloblasts; Hb, hemoglobin concentration; ret, reticulocytes; MCV, mean corpuscular volume; 
WBC, white blood ceii-<:Ount; PI, platelet count. 
Results 
Patients 
According to the F AB criteria patient 1 was classified as RAEBt, patients 2 and 3 as 
RAEB and patients 4, 5 and 6 as RARS. The median myeloblast cell count was 4.0% 
(0.4-13.6), erythroblast count 52.6% (22.8-62.4), hemoglobin concentration 4.1 
mmol/1, MCV 106 £1, reticulocyte count 17%, white blood cell-count 3.0 x 109/1 and 
platelet count 56 x 109 /1. Patients 1,2,3 and 6 had a Boumemouth score of 3 or 4, 
whereas in patients 4 and 5 a score of 1 was found (Table 1). 
Patients 1 and 2 progressed to an AML-M2 during their clinical course, within 2 and 
15 months respectively. Complete remission was achieved in patient 1 after one 
course of chemotherapy and in patient 2 after two courses of chemotherapy. Remis-
sion duration was 5 and 7 months respectively. 
Cytogenetics 
Chromosomal analysis was performed at diagnosis in cases 1 and 2. No chromosomal 
abnormalities were found, in the 32 metaphases investigated in each case. During the 
course of the disease chromosomal abnormalities could be detected in patient 1, in 
which the relapse (RAEBt) bone marrow cells contained a previously absent abnor-
mality i.e.: t(1;2), t(7;13) in 20% of the metaphases. 
Immunologic marker analysis 
The results of the immunological marker analyses, which were performed at the time 
of diagnosis, are given in Table 2. Low percentages of cells expressing the T-cell 
markers CD2 and CD3 were found in all cases except in case 3, in which 47% CD2 
and 41% CD3-positive cells were detected. In all cases low percentages of the B-cell 
markers CDlO and CD19 and the monocytic marker CD14 were found. The majority 
of the mononuclear cells expressed the pan-myeloid markers CD13 and/or CD33. 
The precursor antigen CD34 was present in < 1 - 22% of the cells. Less than 5% 
CD34-positivity was found in cases 3 and 4 (both RARS), whereas a percentage of 
above 10% was found in cases 1, 2 and 3 (RAEB and RAEBt cases). Expression of 
TdT was found in 0.1 - 11% of the cells . 
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Table 2: Immunological marker analysis of patients with MDS at the time of diagnosis 
Percentage of MNC and TdT + cells positive for surface marker 
Patient Stage TdT C02 CD3 CD7 CD10 CD19 CD13 CD14 CD15 CD33 CD34 HLADR GpA 
1. M.M.b RAEBt 11 9(0.5} 10 10(5} <1(0.5} 8(0} 2(39} 2(0} 38(0} 57(97} 22(88} 32(26} 13 
2. S.M. RAEB 0.1 8(1} 6 10(21} < 1 (11) 3(0} 4(45} 8(0} 21 (1} 79(87} 10(93} 19(73} 29 
Ut 
""' 2. S.M. AML 29 8 1 67(63} 4 27 80(99} 55 
3. J.N. RAEB 2.5 47 41 43 <1(6} 6 7 <1 19 37(58} 15(99} 47 2 
4. H.F. RARS 0.1 8 12 11 <1(5} 5 26 2 46 50(9} 4(38} 16 8 
5. H.B. RARS 0.1 18 14 16 < 1 (53} 3 20 7 48 32(2} <1 (11} 25 <1 
6. N.K. RARS 5 12 12 10 <1 (9} 2 32 23 10 48(93} 8{68} 9 2 
a. Percentages positivity for surface membrane marker per TdT-positive cells as determined by DIF staining. 
b. At end stage disease, diagnosed as AML-M2, 25% CD33+,TdT+ cells were detected. 
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Using DIF staining it was found in 4 cases (1-3 and 6) that the majority (58 - 99%) of 
the TdT+ cells were positive for CD13 and/or CD33, but negative for CD10 
(MM + jTdT +) and 68 - 99% of the TdT + cells were positive for the precursor 
antigen CD34. However, in cases 4 and 5, in which 0.1% TdT + cells were detected, 
only 9.3 and 2.0% of the TdT+ cells were CD33 positive, whereas 11 and 38% of the 
cells were found to have the CD34+ /TdT+ phenotype. 
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Figure 1: Follow-up of BM samples of patient 2 by use of DIF staining for TdT and 
the myeloid marker CD33. Clinical phase is based on both clinical observation and 
cytomorphology of BM (closed circles) and PB samples (open circles). PR =partial 
remission, CR = complete remission, Re = relapse, Rx = start chemotherapy, Stop 
Rx = end of chemotherapy. GM-CSF = granulocyte-macrophage colony-stimulating 
factor, LD Ara-C = low dose cytosine arabinoside, HU = hydroxyurea. 
Follow-up studies of two MDS patients 
In order to monitor the MM + /TdT + subpopulation follow-up DIF studies were 
performed in patients 1 and 2. In patient 1 the CD33 + /TdT + population increased 
from 11% in the RAEBt to 25% in the AML-M2 stage of the disease. As depicted in 
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figure 2, in patient 2 the CD33+ /TdT+ subpopulation, which made up 0.1% of the 
cells in the RAEB phase, gradually decreased to below detection at the end of 
induction therapy when this patient was in complete remission, subsequently 
CD33 + /TdT + cells became detectable again 6 months before relapse RAEB. This 
MM + /TdT + subpopulation rapidly expanded to 35% in the terminal AML-M2 
phase. 
Discussion 
The objective of this study was to determine whether MM + /TdT + cells are detec-
table in MDS. We therefore analysed by DIP stainings six MDS cases ( one RAEBt, 
two RAEB and three RARS ), and performed follow up studies in two cases, which 
eventually evolved in an AML. TdT-positivity was found in 0.1 - 11% of the cells. In 
the two RAEB cases and the RAEBt case the majority of the TdT + cells were 
positive for CD13 and/or CD33, which are myeloid surface-antigens that have not 
been found on normal T or B lymphocytes (18), indicating that the TdT + cells belong 
to the myeloid differentiation lineage. Interestingly, CD34 expression was found in 
88 - 99% of the TdT + cells in these three cases. CD34 is expressed by progenitor 
cells in normal bone marrow as well as immature acute leukemias (19). Therefore, it 
is likely that the CD34+ /TdT+ represent a immature subpopulation within the MDS. 
It is unlikely that TdT + cells expressing CD 13 and/ or CD33 are residual normal 
elements within the bone marrow, since MM + /TdT + is detected in normal bone 
marrows in extreemly low fequency, if detected at all (20,21). Moreover, in patients 1 
and 2 MM + /TdT + cells could be detected in MDS and AML phase of the disease. 
In patient 1 the percentage of MM + /TdT + cells increased from 11% in MDS to 
25% in AML. In patient 2 the MM+/TdT+ subpopulation was 0.1% at diagnosis, 
markedly reduced during remission and rapidly increased before relapse RAEB and 
further increased to 35% in parallel with progression to AML. These data strongly 
suggest that MM + /TdT + cells represent an abnormal myeloid subpopulation, which 
might belong to the leukemic clone and is already detectable in MDS. Furthermore, 
double marker analysis for a myeloid marker and TdT may be useful to monitor this 
abnormal subpopulation during disease progression. 
In two of the three RARS cases only a minority of the TdT + cells were found to be 
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CD33 positive. The percentage MM + /TdT + cells in these two RARS cases did not 
exceed the percentages that are found in normal bone marrows (20,21). 
This is in agreement with the observation that RARS is less often accompanied by 
dysgranulopoiesis (22,23). Gatterman et al. (24) have recently distinguished on 
cytomorphologic grounds between pure sideroblastic anemia (PSA), which is confined 
to dyserythropoiesis and RARS, which is characterized by additional dysplastic 
features of granulopoiesis and/or megakaryopoiesis. Both PSA and RARS are 
diagnosed in the same MDS group (MDS 2 or RARS), but the authors found striking 
differences in the risk of leukemic transformation and survival. In this respect it is of 
interest that we found 5% MM + /TdT + cells in the RARS case with an abnormal 
granulopoiesis (case 6), suggesting that the presence of MM + jTdT + cells can 
discriminate between RARS cases with and without an abnormal granulopoiesis. 
Remarkebly, in the latter case a high Boumemouth score was found, indicating a 
worse prognosis than the former two RARS cases with low Bounemouth scores. 
These preliminary results suggest that the presence of MM + jTdT + cells may 
correlate with prognosis. Further studies, however, are required to determine the 
prognostic significance of MM + jTdT + cells in MDS. 
In conclusion our results demonstrate that MM + jTdT + subpopulations occur in 
MDS cases, with an abnormal granulopoiesis and the size of this subpopulation 
increases in parallel with progression of MDS to AML. These results suggests that 
MM + jTdT + cells represent abnormal myeloid cells in MDS. Follow-up studies in 
two cases demonstrated the feasability to monitor this abnormal subpopulation by 
DIF staining during the course of the disease. 
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SUMMARY 
In an agar-liquid double-layer colony assay in which myeloid leukemia colony forming 
cells require the presence of both the lectin PHA and colony stimulating factor ( CSF) 
for in vitro proliferation, colony formation of bone marrow cells derived from patients 
with a myelodysplastic syndrome (MDS) was studied. 
In five of 14 MDS and all five leukemic transformed MDS cases, colony formation was 
found to require both PHA and CSF. Three of these five PHA dependent MDS cases 
progressed to overt leukemia within 1 year, one progressed from RA to RAEB, one 
patient received AML chemotherapy. PHA-dependent colony formation was associated 
with higher bone marrow blast counts, but not directly to F AB type or cytogenetic 
abnormalities. In nine other MDS cases only CSF was required for colony formation. In 
these PHA-independent cases the course of the disease was stable during the observation 
time (5-17 months). Two types of colonies were observed in this in vitro system: colonies 
adherent and colonies nonadherent to the agar under layer. The former consisted of 
terminally differentiated myeloid cells, and the latter comprised immature cells. This 
suggests that the percentage adherent colonies formed in vitro may be used as a measure 
for the maturation defect in MDS. However, no correlation was found between the 
percentage adherent colonies and progression to leukemia of the MDS cases. Our 
findings suggest that the dependency on PHA for in vitro colony formation of colony-
forming cells in MDS is predictive for the progression to leukemia. However, the in vitro 
differentiation capacity has no apparent prognostic significance. 
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INTRODUCTION 
The MDS has been subdivided into five clinical entities on morphological criteria by the 
French-American-British (FAB) cooperative group (1,2). Patients suffering from MDS 
have a variable clinical course. The high mortality rate results form the complications 
associated with persistent cytopenias, as well as from leukemic transformation (3). 
Prognosis has been associated with the percentage of blast cells in bone marrow and 
blood ( 4), cytogenetic abnormalities (5), and in vitro growth patterns of bone marrow 
cells (6,7). 
The formation of granulocyte-macrophage colonies in the Robinson assay system (8) has 
been reported to be abnormal in fifty to ninety per cent of the MDS patients. The 
abnormal in vitro colony growth of MDS bone marrow (i.e. absent or severely reduced 
colony formation, or an increased cluster/colony ratio) resembles that of AML (9-13). 
An abnormal in vitro growth pattern tends to be correlated with poor prognosis (12,13). 
In vitro maturation defects are observed both in semi-solid and liquid culture (14,15). 
Since colony formation of AML bone marrows in standard semisolid assays is very poor, 
two types of colony culture assays for AML-CFCs have been developed (16,17). Both in 
the PHA-leukocyte feeder layer assay and the PHA assay described by Dicke et al. (16) 
the AML-CFCs were found to be of a low boyant density. In addition, it is suggested that 
AML cells giving rise to colonies in a PHA assay and the Robinson assay represent 
distinct leukemic subpopulations (18). Spitzer et al. (19) have studied a small series of 
oligoblastic leukemia patients at diagnosis with a two-step PHA assay. In a group of 10 
patients those with PHA colonies appeared to follow a more rapid clinical course than 
those without PHA colonies. This finding suggests that the assay detects a leukemic 
subpopulation with greater proliferative potential than the majority of the leukemia (19). 
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No reports, that we have knowledge of, describe the characteristics of colony formation 
of MDS bone marrow in a PHA assay. We used a modified one-step PHA assay to 
investigate the growth and differentiation of this specific subset of progenitors in MDS 
and LT-MDS bone marrow and compared this with the morphological classification 
according the criteria of the F AB group, bone marrow blast counts, the presence of 
cytogenetic abnormalities and the relation to the clinical course of the disease during the 
follow-up period. 
MATERIAL AND METHODS 
Patients 
Seventeen patients (ages 17-84 years) with a primary myelodysplastic syndrome, four 
patients with leukemic transformation of a MDS, five de novo AML patients and seven 
normal controls were studied at diagnosis. Follow-up culture studies were performed in 
two MDS cases (24 and 28), and two leukemic transformed MDS cases before and after 
relapse (31 and 32). Informed consent was obtained according the Helsinki convention. 
Relevant clinical and hematological data are given in Table 1. The MDS and AML were 
classified according the F AB nomenclature (1,2). Controls had no hematological 
malignancy and had normal bone marrow morphology. 
Bone marrow cells 
Bone marrow of patients was aspirated from the posterior iliac spine as part of diagnostic 
investigations. Aspirates were collected in glass tubes containing preservative-free 
heparin. Mononuclear cells with a density less than 1.077 gjml were prepared by layering 
the bone marrow cells on Ficoll-isopaque and subsequent centrifugation (20 min, 1000 
g). T cell depletion of the mononuclear cells was performed by E-rosette Ficoll 
separation. Rosettes were prepared by incubating the mononuclear cell suspensions (2 
x 106) with 1% v jv 2-aminoethylisothioranium bromide treated sheep erythrocytes for 5 
min. This mixture was layered on Ficoll (1.077 g/ml) and centrifugated for 20 min, 1000 
g. Subsequently, the interphase fraction, now depleted of rosette forming cells, was 
collected. In addition, adherent cells were removed from the T cell depleted 
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Table 1. Clinical, Hematological, and Cytogenetic Data at Time of Study and Results of C.olony Assays in Individual Patients 
Age Bone Marrow Colony Formation Type of Case Pt. no ... Sex (yr) FAB
0 
%Blasts Cytogenetics +PHAc -PHAd %Adh.0 
NBM 1 F 78 1.0 NO' 528 304 97 
2 F 39 1.0 NO 1271 1302 65 
3 F 26 0.3 NO 99 116 91 
4 M 33 0.5 NO 255 174 90 
5 F 32 0.2 NO 450 432 100 
6 F 32 0.8 NO 337 NO 100 
7 F 71 0.2 NO 671 NO 89 
AML 8 M 66 M4 68 n' 547 0 3 
9 M 47 M1 81 inv.16(pl3-q22) 3 0 0 
10 M 20 M4 89 t(8;13;17) 86 0 0 
11 M 51 M4 64 59 7 8 
12 M 45 M2 72 n 11 4 20 
MOS during 13 F 84 RAEB 6.6 NO 140 NO 74 
stable course 14 F 79 RAEB 5,2 n 201 NO 79 
15 M 78 CMML 0.4 -y/-y, +8 (10%) 402 NO 98 
16 F 74 RAEBt 24.0 n 202 122 12 
17 M 53 RARS 0.2 n/+8 (3%) 483 453 41 
18 M 65 RARS 5.0 n 84 116 4 
19 M 82 RARS 1.2 NO 142 145 26 
20 F 77 RA 2.4 NO 89 120 97 
21 M 81 RAEB 11.2 nldel(7), del 53 40 8 
(20)/t(3;17), 
del(?), del(20) 
22 M 77 RAEB 15.0 n 76 67 25 
23 M 72 RAEB 5.2 n/45 XO (13%) 81 33 54 
24a M 73 CMML 0.4 419 360 87 
24b CMML 5.8 87 20 37 
24c CMML 1.0 407 275 50 
MOS with 25 M 83 RAEB 20.0 n 123 9 99 
progresston 26 M 35 RAEB 20.0 nl-7 (7%)1 180 0 26 
+8 (66%) 
27 M 71 RA 5.0 117 0 82 
28a M 37 RAEB 13.0 32 2 32 
29 M 17 RAEBt 23.4 n 11 0 79 
LT-MOS 30 M 40 M2 42.0 t(8;21) 441 NO 51 
31a F 38 M5 66.0 n/+8 (10%) 363 9 36 
31b M2 40.4 n/+8 (4%) 7 0 79 
32a F 40 M7 50.3 60 3 51 
32b M2 33.0 n 47 0 0 
33 M 78 M2 60.0 complex tetraploid 156 0 41 
28b M 37 M2 31.6 NO 240 3 80 
o'JPt. no., patient numbers: each number indicates _a patient. a, b, and c indicate follow-up culture studies during the course of the disease. 
°Ciassifications not defined here are either listed in the text abbreviations footnote or else are standard abbreviations. RAEBt, RAEB in transformation. 
cMean number of colonies of three counted dishes per 105 plated cells in the presence of 10% GCT-CM and 1% PHA. 
dMean number of colonies formed in the presence of 10% GCT-CM. 
"% Ad h., mean percentage of adherent colonies formed in the presence of 1 0%· GCT -CM and 1% PHA. 
1ND, not determined. 
on, normal karyotype 46, XY or 46,XX. 
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mononuclear cells by incubating the cell suspensions for 2 hr at 37°C, in a fully 
humidified atmosphere with 5% C02 in air in plastic culture flasks (Costar, 75 cm2, 1 x 
106 nucleated cells/ml in culture medium with 10% serum). 
Colony assay 
Myeloid colonies were grown in a liquid agar double-layer culture. T cell depleted, 
nonadherent mononuclear bone marrow cells (1 x 105) were cultured in a 0.4 mlliquid 
upper-layer in the presence or absence of 1% (vjv) PHA. The 0.5% agar under-layer 
contained various concentrations (1 - 20%, but 10% when not specified) of conditioned 
medium of the giant tumor cell line (Gibco Cat. no. 680-1000) as a source of CSF in a 
volume of 1 ml in plastic culture dishes (Costar diameter 35 mm). The culture medium 
consisted of the a-modification of Dulbecco's modified Eagle's MEM, 20% human AB 
serum (a constant pool) and 10% of a mixture composed of 10% BSA (Fraction 5), egg 
lecithin (3.75 x w-3 M), Na2Se03 (1.25 x 10-5 M), human transferrin (9.62 x 104 M) in a 
FeC13 solution (1.92 x 10-3 M) and ,8-mercaptoethanol (10"1 M) in ratios of respectively 
75:8:8:8:1. The culture dishes were incubated in a fully humidified atmosphere of 5% 
C02 in air at 37°C for 7 days. Colonies of more than 50 cells were scored using an 
inverted microscope. The total number of colonies were counted and subsequently 
colonies adherent to the agar underlayer were identified and counted after removal of 
the non-adherent colonies with a Pasteur pipet. Mter counting, the adherent colonies 
were mass harvested with a Pasteur pipet. Aliquots of single cell suspensions of both 
non-adherent and adherent colony cell suspensions were used for the preparation of 
cytospin slides. Mter metachromatic staining (May-Griinwald Giemsa ), the morphological 
maturation stage of the colony cells was determined. In some cases, intact colonies were 
plucked for assessment of the morphological maturation stage of single colonies. The 
presence of T cells in colonies was tested by E-rosette formation. 
Cytogenetics 
Cytogenetic analyses of patients bone marrow cells were done according to our standard 
technique (20) as part of the diagnostic investigation. Chromosomes were always 
identified by banding techniques (R-, Q- and G-bands) and according to the ISCN (21). 
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RESULTS 
Dependency on PHA for colony formation 
All 17 MDS bone marrows formed colonies in the presence of PHA and GCT-CM. The 
mean number of colonies was 176 ± 140 (mean ± 1 SD)/ 1 x 105 cells plated. A 
representative GCT-CM dose response curve is shown in Figure 1. The 5 LT-MDS cases 
formed an average of 188 ± 155 colonies under the same culture conditions, whereas the 
seven normal and the five AML bone marrows formed respectively 516 ± 353 and 141 
± 205 colonies/105 plated cells. Colony cells contained always less than 1% E-rosette 
forming cells. 
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Figure I. Dose response curve of colony fonnation stimulated with 
increasing concentrations of GCT-CM in the presence of 1% PHA. 
Each point represents the mean of triplicate counts ( + I SD) of 
colony culture of bone marrow derived from patient no. 18. 
In the absence of PHA, but in the presence of GCT-CM, very few or no colonies were 
formed in all AML, all LT-MDS cases and five of 14 MDS cases. In seven MDS cases 
no enhancing effect of PHA on colony formation was observed. In two cases (16 and 23) 
an increase of colony numbers was found in the presence of PHA, but these cases were 
not classified as PHA-dependent because a substantial number of colonies (> 10) was 
formed in the absence of PHA. 
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Follow-up culture studies of individual cases showed no alterations in the growth 
patterns. Hence, colony formation remained PHA independent (case 24), or was PHA 
dependent before and after progression to leukemia (cases 28a and 28b ), or was PHA 
dependent on two different time points in the leukemic phase (i.e. before and after 
relapse) of the disease (cases 31, 32). No cases were observed where the colony 
formation pattern changed from a PHA independent to a PHA dependent one during 
the observation time. 
Colony adherency 
Two types of colonies were observed in this colony assay: those that were adherent to 
the agar underlayer, and those that were nonadherent. Colonies that were adherent to 
the agar underlayer consisted of terminally differentiated myeloid cells (Table 2). 
Invididual adherent colonies were found to contain either macrophages, or a mixture of 
granulocytes and 
Table 2: 
non-adherent 
adherent 
The average percentages mature cells present in non-adherent and 
adherent colonies and the granulocyte-macrophage ratio of the mature 
cells 
NBM (n=4) MDS (n=8) 
% maturation1 G/M ratio % maturation G/M ratio 
100 3.3 32.2 0.87 
(99-100) (2.6-4.3) (1.3-59.6) (0-2.0) 
97 0.8 92.4 0.2 
(94-99) (0.42-1.2) (83-100) (0-0.9) 
I. Mature cells are defined as bands, PMN granulocytes or macrophages. 
macrophages. Non-adherent colonies ofMDS cultures were predominantly composed of 
immature cells (Table 2). In the AML group virtually no adherent colonies were found. 
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The nonadherent colonies consisted of blast cells, whereas in normal bone marrow 
cultures these colonies contained predominantly mature granulocytes (bands and PMN 
cells). The differentiation stage of the majority of the non-adherent colony cells in MDS 
was intermediate to that of NBM and AML (i.e., promonocytes, promyelocytes, meta-
and myelocytes). A dose response relation was found between the percentage adherent 
colonies and the concentration GCT-CM (Table 3). PHA did not have an enhancing 
effect on the formation of adherent colonies (Table 3). These results indicate that the 
percentage adherent colonies formed in this assay may be used as a measure of the in 
vitro maturation of the colony cells. 
Table 3: Percentage adherent colonies 
formed in the presence of 
increasing concentrations of 
GCT-CM 
% 
PHA 
1 
1 
1 
0.1 
0.0 
I. 
2. 
% 
GCT-CM 
1 
3 
10 
10 
10 
Culture1 
24a 24b 24c 
8 7 17 
23 6 70 
87 37 50 
81 nd2 nd 
74 25 79 
colony assays were perfonned at three 
different times with bone marrow cells of 
patient no. 24 (see Table 1). 
nd = not detennined. 
In the presence of 10% GCT-CM and 1% PHA, the mean percentage adherent colonies 
formed in the MDS group was 53% (range 4-99%) and 48% (0-80%) in the LT-MDS, 
versus 90% (65-100%) in the NBM and 6% (3-20%) in the AML group (Fig. 3). With 
1% GCT-CM the mean percentage adherent colonies in the MDS group was 28% (range 
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1-100%), whereas in the NBM group this figure was 75% (range 49-100%). These results 
suggest that in MDS both the in vitro maturation capacity and the maturational 
responsiveness upon the GM-CSF stimulus are reduced. 
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Figure 2. Percentage colonies adherent to the agar under 
layer in the presence of 10% GCT-CM as a source of 
GM-CSF and 1% PHA. Horizontal lines indicate the 
averages of each group. 
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Relation of colony formation pattern and the evolution to overt leukemia 
A positive correlation was found between PHA dependency for colony formation and the 
progression to overt leukemia in three cases (cases 25, 26 and 28). One of the five MDS 
cases that had a PHA-dependent colony formation pattern, progressed from RA to 
RAEB (case 27), and one had originally been classified as M6 (case 29), but was later 
reclassified as a RAEBt. This last patient received chemotherapy, but did not reach 
complete remission. The bone marrow morphology after chemotherapy met again the 
criteria for RAEBt. 
In all 14 PHA-independent cases the course of the disease was stable during the 
observation time of 5-17 months. 
PHA-dependent colony formation in MDS cases was related to a higher bone marrow 
blast count as compared to PHA-independent cases (mean 16.3 versus 7.1). However, no 
obvious relationship was observed between the FAB type and colony formation pattern. 
No PHA-dependent cases were present in the RARS or CMML groups. The incidence 
of progression to leukemia in RA and RAEB varies considerably. In these prognostic 
heterogenous MDS subgroups, the PHA-dependency for colony formation may separate 
patients with a better or worse prognosis. Only in one of the PHA dependent MDS cases 
an abnormality was found during the karyotype analysis at the time of culture (case 26). 
Compared with NBM, the mean percentage adherent colonies was decreased both in the 
MDS and the LT-MDS group. Progression to leukemia occured in cases with a high 
(cases 25, 27 and 29) and a low (cases 26, 28a) percentage adherent colonies. Hence, no 
apparent correlation exists between the percentage adherent colonies and the progression 
to leukemia. 
DISCUSSION 
The presented results indicate that MDS patients may be classified, irrespective of the 
F AB class, on the basis of the PHA dependency for in vitro colony formation, in a group 
with a low risk and a group with a high risk for progression to leukemia. PHA 
dependency correlates with a higher average bone marrow blast count, but not directly 
with the F AB type or the presence of cytogenetic abnormalities. 
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The number of blast cells in bone marrow and blood is reported to be an important 
prognostic parameter ( 4). In the RA case (no. 27), however, PHA dependent colony 
formation was found, whereas the bone marrow blast count was low (5%). In this case 
we observed progression to RAEB, indicating that the PHA dependent in vitro growth 
pattern precedes the in vivo accumulation of blasts in the bone marrow, rather than 
being the result of increased numbers of blast cells in the cultured cell suspension. 
PHA independent growth with a high percentage adherent colonies was related to a 
normal growth pattern in the Robinson assay (data not shown). Both PHA independent 
cases with a low maturation capacity and PHA dependent cases were found to have an 
abnormal growth pattern in the Robinson assay. This indicates that a further discrimina-
tion on the basis of PHA dependency is possible of cases with abnormal growth in the 
standard colony assay. 
The presence of cytogenetic abnormalities is also valued to be an important prognostic 
parameter in MDS (13). However, we found no direct relationship between karyotype 
and in vitro growth pattern. This could indicate that growth characteristics of the MDS 
progenitor cells do not causally relate to the cytogenetic abnormalities found in MDS. 
The reduced differentiation capacity of MDS CFCs, as measured by the percentage 
adherent colonies, may reflect the in vivo maturation disorder in MDS. The mean 
percentages of adherent colonies of the MDS and LT-MDS groups are comparable, 
whereas this figure is much lower in the AML group. Three of the five PHA-dependent 
MDS cases (cases 25, 27 and 29) have a high percentage adherent colonies (Table 1). 
Moreover, sequential studies do not show a consistent decrease in percentage adherent 
colonies before progression to overt leukemia or during the leukemic phase of MDS 
(Table 1). It is therefore unlikely that the reduced maturation capacity in MDS is directly 
related to the progression to leukemia. 
Recently, it has been reported that patients with apparently de novo AML with features 
of trilineage MDS differ from those without associated trilineage MDS (22). 
Biologically, this newly defined group is comparable to the LT-MDS group described 
here. It is therefore of interest that we found a higher maturation capacitiy in the 
LT-MDS group as compared to the AML group, suggesting that also on basis of in vitro 
growth pattern the former may be separated from the latter. 
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The implications of our findings for an understanding of MDS and its progression to 
acute leukemia may be as follows. One possible explanation for the leukemic 
transformation is the intensification of the maturation block, but our results do not 
support this, since the differentiation capacity of the CFCs before and after progression 
to leukemia is comparable. Apparently, more important is the PHA dependency for 
colony formation. This growth pattern seems to be directly related to the progession to 
leukemia. It is therefore of interest to investigate the nature of this PHA effect. It has 
been reported that leukemic blast progenitor cells require the presence of CSF and cell 
to cell interactions for exponential growth (23). PHA may very well induce cell-cell 
interactions and subsequently proliferation in the presence of CSF. Preliminary results 
in our laboratory are in support of this view. However, PHA may be a message on its 
own or may induce the release of soluble factors by accessory cells. Another question to 
address is whether this is a a unique "leukemic" feature or whether a similar type of cell 
exists in normal bone marrow. Normal multipotent stem cells have been described that 
only respond to M-CSF when concommitantly cultured in the presence of IL-l (24). IL-l 
is reported to exhibit lectin- like specificity (25). PHA may therefore induce similar 
effects in this culture assay. It is tempting to speculate that the normal biological 
counterpart of the PHA dependent CFC is the multipotential stem cell. 
Our results show that MDS and LT-MDS have a comparable reduced in vitro 
differentiation capacity. The maturation capacity is not further altered when progression 
to leukemia occurs. But PHA dependency is clearly related to an impending progression 
to leukemia. Further studies are required to reveal the mechanism of action of PHA and 
to determine the prognostic value of PHA dependency for colony formation. 
ACKNOWLEDGEMENTS 
We thank Prof.Dr. 0. Vos for critically reveiwing the manuscript. Mrs. N. Vink for her 
excellent technical assistance, Mrs. K. van Lorn for the enthusiastic support during the 
course of this work and Mrs. C.J.M. Meijerink-Clerkx for typing the manuscript. 
This investigation was in part supported by the Netherlands Cancer Foundation 
(Koningin Wilhelmina Fonds, IKR 84-3). 
69 
REFERENCES 
1. Bennett JM, Catovsky D, Daniel MT, Flandin G, Galton DAG. Proposals for the classification of 
the myelodysplastic syndromes. Br J Haematol 1982; 51: 189. 
2. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG. Proposed revised criteria for the 
classification of acute myeloid leukemia. Ann Intern Med 1985; 103: 626. 
3. Galton AG. The myelodysplastic syndromes. Clin Lab Haematol1984; 6: 99. 
4. Kerkhofs M, Hermans J, Haak ID, Leeksma HW. Utility of the FAB classification for the 
myelodysplastic syndromes: Investigation of prognostic factors in 237 cases. Br J Haematol1987; 65: 
73. 
5. Tricot G, Boogaerts MA, DeWolf-Peeters C. The myelodysplastic syndromes: different evolution 
patterns based on sequential morphological and cytogenetic investigations. Br J Haematol1985; 59: 
659. 
6. Verma DS, Spitzer G, Dicke KA, McCredie KB. In vitro agar culture patterns in preleukemia and 
their clinical significance. Leuk Res 1979; 3: 41. 
7. Partanen S, Juvonen E, Ruutu T. In vitro culture of haematopoietic progenitros in myelodysplastic 
syndromes. Scand J Haematol 1986; suppl.45: 36: 98. 
8. Pike BL, Robinson WA. Human bone marrow colony growth in agar-gel. J Cell Physiol1970; 76: 
77. 
9. Greenberg PL. The preleukemic syndrome. Am J Med 1979; 66: 951. 
10. Milner GR, Testa NH, Geary CG, Dexter TM, Mulda S, Maciver JE, Lajtha LG. Bone marrow 
culture studies in refractory cytopenia and smouldering leukemia. Brit J Haematol 1977; 35: 251. 
11. Koeffier HP, Golde DW. Human preleukemia. Ann Intern Med 1980; 93: 347. 
12. Francis GE, Miller EJ, Wonke B, Wing MA, Berney JJ, Hoffbrand AV. Use of bone marrow 
culture in prediction of acute leukemic transformation in preleukemia. Lancet 1983: 1409. 
13. Gold E, Conjalka M. Pelus LM, Jhanwar SC, Broxmeyer H, Middleton AB, Clarkson BD, Moore 
MA. Marrow cytogenetics and cell culture analysis of the myelodysplastic syndromes. Insight to 
pathophysiology and prognosis. J Clin Oncol 1983; 10: 627. 
14. Koeffier HP, Golde DW. Cellular maturation in human preleukemia. Blood 1978; 52: 355. 
15. Lidbeek J. In vitro colony and cluster growth in haemopoietic dysplasia (the preleukemic syndrome). 
ll: Identification of a maturation defect in agar cultures. Scand J Haematol. 1986; 25: 113. 
16. Dicke KA, Spitzer G, Ahearn MJ. Colony formation in vitro by leukemic cells in acute myelogenous 
leukemia with phytohaemagglutinin as stimulating factor. Nature 1976; 259: 129. 
17. Lowenberg B, Hagemeijer A. Colony formation of human acute leukemia cells in vitro. In 
Bentvelzen P, Hilgers J, Yon DS (eds). Advances in comparative leukemia research, Amsterdam: 
Elsevier, 1977:274. 
70 
18. Swart K, Hagemeijer A, U\wenberg B. Acute myeloid leukemia colony growth in vitro: Differences 
of colony forming cells in PHA-supplemented and standard leukocyte feeder cultures. Blood 1982; 
59:816. 
19. Spitzer G, Verma DS, Dicke KA, McCredie KB. Culture studies in vitro human leukemia. Sem 
Hematol 1978; 15: 355. 
20. Hagemeijer A, Smit EME, Bootsma D. Improved identification of leukemic cells in methotrexate 
treated cultures. Cytogenet Cell Genet 1979; 23: 208. 
21. Hainden DG, Klinger HP eds. ISCN (1984). An international system for human cytogenetic 
nomenclature. Published in collaboration with Cytogenet Cell Genet. Basel: Karger, 1985. 
22. Brito-Babapulla F, Catovsky D, Galton AG. Clinical and laboratory features of de novo myeloid 
leukemia with trilineage myelodysplasia. Br J Haematol 1987; 66: 445. 
23. Nara N, McCulloch EA. Membranes replacce irradiated blast cells as growth requirement for 
leukemic blast progenitor cells in suspension culture. J Exp Med 1985; 162: 1435. 
24. Bartelmez SH, Stanley ER. Synergism between hemopoietic growth factors (HGF's) detected by 
their effects on cells bearing recptors for a lineage specific HGF: Assay of hemopoietin-!. J Cell 
Physiol 1985; 122: 370. 
25. Muchmore A V, Decker JM. Evidence that recombinant IL-1 exhibits lectin-like specificity and binds 
to homogenous uromodulin via N-linked oligosaccharides. J lmmunol 1987; 138: 2541. 
71 
72 
CHAPTER4 
THE EFFECTS OF IL-3, GM-CSF AND G-CSF ON THE GROWTH KINETICS OF 
COLONY FORMING CELLS IN MYELODYSPLASTIC SYNDROMES 
Martin Schipperus\ Pieter Sonneveld\ Jan Lindemansl, Anne Hagemeijer2 , Nel 
Vink\ Johannes Pegels3 and Johannes Abels1 
Department of 1Hematology· 2Cell Biology and Genetics· Erasmus University 
Rotterdam and the 3St.Franciscus Gasthuis Rotterdam· The Netherlands. 
Published in Leukemia, 1990; 4: 267 - 272 
73 
ABSTRACT 
In order to obtain more insight into the nature of the abnormal in vitro colony 
formation in Myelodysplastic syndromes (MDS) we investigated the kinetics of the 
colony formation of 23 MDS cases in response to recombinant human 11-3 (11-3), 
granulocyte-macrophage colony stimulating factor (GM-CSF), granulocyte colony 
stimulating factor (G-CSF) and giant cell tumor cell line conditioned medium (GCT-
CM). The kinetics of GCT-CM induced colony formation were comparable to that of 
G-CSF-induced colony growth, both in MDS and in normal bone marrow cultures. 
Colony formation was found to be delayed in MDS. The delay in colony formation 
was most apparent in the GCT-CM responsive progenitor cell compartment. In MDS 
cases with clinical features of high risk disease this delay was more pronounced as 
compared to low-risk cases ( 7 and 3 days respectively, in response to GCT-CM). The 
delay in colony formation was found to be caused by an increase in the time interval 
before progenitor cells begun to divide. These results suggest that a prolongation of 
the time spend in Go of myeloid progenitor cells in MDS may be the cause of the 
indolent in vitro colony formation observed in this disease. 
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INTRODUCTION 
The myelodysplastic syndrome is a clonal disorder of the hemopoietic stem cell (1) 
resulting in cytopenias of one or more cell lineages. In vitro a reduced myeloid and 
erythroid colony formation is observed (2,3). The reduced colony formation may be 
due to intrinsic abnormalities of the progenitor cells such as an altered re~ponsiveness 
for hemopoietic growth factors caused by abnormalities of the growth factor receptors 
or of the signal transduction system. We (4) and others (5) have previously reported 
that the responsiveness for hemopoietic growth factors is indeed altered in MDS. 
Experiments performed by Francis et al. (6) suggest that mature progenitor cells are 
more sensitive to hemopoietic growth factors than immature progenitor cells. Suda et 
al. reported (7) that in mice multipotential stem cells are in Go for varying periods of 
time, whereas the doubling time is constant. Furthermore, recent investigations 
suggest that only the early G1 phase of the cell cycle is permissive for the stimulation 
with colony stimulating factors (8). Hence, alterations in the cell cycle status of 
progenitor cells may result in an alteration in the responsiveness for hemopoietic 
growth factors. 
The aim of the present experiments is to investigate the kinetics of colony formation 
in MDS in response to recombinant human hematopoietic growth factors. We 
therefore compared the colony formation kinetics of MDS bone marrow in response 
to recombinant human interleukin-3 (Il-3), granulocyte-macrophage colony- stimula-
ting factor (GM-CSF), granulocyte colony-stimulating factor (G-CSF) and the 
conditioned medium of the giant cell tumor cell line (GCT-CM) with normal bone 
marrow cells (NBM) and NBM cells depleted of committed progenitor cells by in 
vitro exposure to 4-hydroperoxycyclophosphamide. 
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MATERIALS AND METHODS 
Normal donors. Normal marrow samples were obtained from six healthy volunteers 
upon informed consent by posterior iliac crest puncture. The marrow was collected in 
glass tubes containing Hanks/Hepes with preservative-free heparin. 
Patients. Seventeen patients with MDS and six patients with leukemic transformation 
of MDS (LT-MDS) were studied. The MDS cases were classified according the FAB 
nomenclature (9). Relevant clinical and hematological data are given in Table 1. 
On the basis of clinical, cytogenetic and hematological data, patients were divided 
into a MDS low risk and a MDS high risk group. Criteria for the high risk MDS 
group were: the presence of more than 10% blast cells in the bone marrow or the 
presence of blast cells in the periferal blood, complex cytogenetic abnormalities or 
transformation to overt leukemia during the observation time. The low risk MDS 
group did not have these features and had a stable clinical course during the obser-
vation time. 
Preparation of cell suspensions. Bone marrow cells of patients and normal donors 
were separated over Ficoll-Isopaque (1.077 gjml, 1,000 g, 20 min); T cell depletion of 
the mononuclear cells was performed by E-Rosette Ficoll separation. Rosettes were 
prepared by incubating the mononuclear cell suspension (2 x 106 jml) with an equal 
volume of 1% (v/v) 2-aminoethylisothiouroniumbromide (Sigma) treated sheep 
erythrocytes for 5 minutes. Rosettes were centrifuged through Ficoll (1.077 gjml, 20 
min 1,000 g). Subsequently, the interphase fraction was collected and washed in 
Hanks/Hepes. In addition adherent cells were removed by incubating the cell 
suspension ( 1 x 106/ ml in o:-Dulbecco's modified Eagle's medium (o:-DMEM) with 
10% fetal calf serum (FCS)) for 1 hour at 37 °C, 5% C02 in air in a fully humidified 
atmosphere. Non-adherent cells were collected and washed twice in Hanks/Hepes. 
Exposure to 4-hydropero:xycyclophosphamide (4-HC). 1 x 107 Light-density, T-cell 
depleted, non-adherent cells were incubated with 60 p.gjml 4-HC (Asta-Werke, 
F.R.G) for 30 minutes at 37°C, washed twice in cold Hanks/Hepes and assayed for 
the recovery of colony forming cells. 
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Table 1. Relevant clinical, haematogical and cytogenetic data of 
patients studied at time of in vitro study 
Patient Bone marrow 
-------------- -------------------------
Group No· Sex Age Dxa % blasts cytogenetics 
Low risk 1 M 17 RA 2.6 not done 
2 F 78 RA 0.4 n 
3 M 73 CMML 0.4 nb 
4 M 68 RARS 0.4 njhypodiploid(17%) 
5 M 60 CMML 1.2 n/46 XY t(1;19) 
(p22;q13) (12.5%) 
6 M 73 RARS 0.6 not done 
7 M 77 RAEB 7.6 46 XY, del (11) 
(q21q24) 
8 M 68 RA 1.5 n 
High risk 9 M 18 RAEB 15.6 n 
10 M 78 RAEB 6.8c n 
11 M 65 RAEBt 21.8 n 
12 M 83 RAEBt 20.0 n 
13 F 38 LT-MDS 40.0 n/47 XX,+8(4%) 
14 M 40 LT-MDS 34.2 nj46X,-Y,t(8;21) 
(20%) 
15 F 75 LT-MDS 30.4 njcomplexd(58%) 
16 F 78 RA_,.L 4.2 n 
17 M 70 RAEB_,.L 8.6 n 
18 F 17 RAEB_,.L 7.2 n 
19 M 68 LT-MDS 77.0 n 
20 M 66 LT-MDS 82.4 n 
21 F 53 RAEB 16.4 n/47 XX,5q-,+21 
(78%) 
22 M 60 RAEBt 20.0 not done 
23 M 56 LT-MDS 38.4 njcomplexe(62%) 
a) RA = Refractory anaemia; RARS = RA with ringsideroblasts, RAEB = RA excess of 
blasts; RAEBt = RAEB in transformation; CMML = chronic myelomonocytic leukemia; 
LT-MDS = MDS after evolution to frank leukemia. RA-+L or RAEB-+L = transformati-
on to overt leukemia occurred in the observation time following bone marrow culture. b) 
Normal karyotype, i.e., 46,XX or 46,XY c) periferal blood blast count = 5.5% d) 43-45, 
XX der(2) t(2;17)(p24;qll), -5,del(7)(q21),-13,16q+,-17, 20p-, +]-markers. MDS 
secondary to intravesical chemotherapy. e) 44,XY,Mar(3),5q-,-7,-12,-16, +dic.Mar-
(16p-+11::7q21-+7pter). 
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Recombinant human colony-stimulating factors. Recombinant GM-CSF was gene-
rously made available by Schering (Kenilworth, NJ) and was used at a concentration 
of lOng/mi. Recombinant G-CSF was purchased from Genzyme (Sanbio bv, Uden, 
The Netherlands) and was used at 100 U/rnl. Recombinant 11-3 was a generous gift 
from Dr G. Wagemaker (Erasmus University, Rotterdam, The Netherlands) and was 
produced by Gist-brocades (Delft, The Netherlands) and used at a concentration of 
10 ng/rnl. All applied concentrations of colony stimulating factors were optimal 
concentrations, as determined by dose-response studies using clonogenic assays on 
normal light-density, T-cell depleted, non-adherent bone marrow cells. 
Giant Cell Tumor-Conditioned Medium (GCT-CM). GCT-CM was prepared by 
culturing the confluent growing GCT cell line (obtained from the American Type 
Culture Collection, ATCC TIB 223) for 7 days with cx-DMEM with 10% FCS (10 rnl 
per 75 cm3) and was used as a source of colony stimulating activity at a concentration 
of 10% v/v. 
Colony assay. Cultures were performed in a-DMEM containing 0.9 % methylcellulose 
(Fluka Methocell MC 4000 mPa's), and supplemented with 20 % FCS, 1% dialyzed 
bovine serum albumin (BSA), 30 JLM egg lecithine, 0.1 JLM Sodiumselenite, 7.7 JLM 
fully iron-saturated human transferrin, 100 JLM mercaptoethanol. Cultures were 
performed in 24-wells plates (Costar), 250 JLl per well containing 2.5 x 104 bone 
marrow cells. The cultures were incubated at 37°C in a fully humidified atmosphere 
of 5% C02 in air. Colonies of more than 50 cells were counted after 7, 10, 14, 18, and 
22 days of culture using an inverted microscope. In selected cases colonies were 
picked from the well for staining with the May-Grunwald-Giemsa technique and 
subsequent morphological examination. 
Cytogenetics. Cytogenetic analyses of bone marrow cells obtained from patients were 
done using a standard technique (10), as part of the diagnostic investigation. Chromo-
somes were always identified by banding (R-, Q-, G-bands). The karyotypes were 
reported according to the "International System for Human Cytogenetic Nomenclatu-
re" (11). In four cases cytogenetic analyses of the colony cells were performed on 
pooled colony cells. 
78 
Statistics. The Fischer exact test and the two tailed Mann-Whitney test were used to 
statistically evaluate the differences in frequency distribution of the day of maximal 
colony formation. 
Figure I. Distribution in time of the number of cases with maximal colony numbers. 
Values represent the number of cases that were observed to have attained maximum 
colony numbers in response to GCT-CM, GM-CSF and Il-3 at day 7, 10, 14, 18 and 22 
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RESULTS 
Kinetics of colony formation in response to GCT-CM. In normal bone marrow 
cultures all cases reached a maximum number of colonies at day 7 (Fig.1). In MDS 
maximum colony numbers were attained at day 7 of culture in two of the eight (25%) 
low risk cases and one of the fifteen (6.7%) high risk cases, which were found to be 
significant differences as compared with the control group (Fisher exact: p < 0.007 and 
p<0.001 respectively). Four of the eight (50%) cases in the MDS group with low risk 
features were found to have reached maximum numbers of colonies at day 10 and 
two of the eight (25%) cases on day 18 of culture. In the MDS group with high risk 
features, 93.3% of the cases had attained the maximum number of colonies on day 10 
or later (i.e day 7: 1, day 10: 2 day 14: 8, day 18: 3 and day 22: 1 of the 15 cases) 
( Fig.1 ). The differences between the two MDS groups did not reach significance. 
Colony numbers were comparable to normal bone marrow in the low risk MDS 
group, but decreased in the high risk MDS group (Table 2). Since GCT-CM was 
found to stimulate a late progenitor cell and the colonies had a granulocytic ap-
pearance, we compared the colony formation kinetics of GCT-CM with that of 
recombinant G-CSF. An identical growth pattern was observed with either GCT-CM 
or G-CSF in normal bone marrow and MDS (Table 3). 
Kinetics of colony formation in response to GM-CSF. As compared with normal bone 
marrow, the number of cases that attained a maximum number of colonies at day 14 
of culture was decreased in both MDS groups: i.e., from three of the five in NBM to 
three of the seven in the low risk and three of the 12 in the high risk group. Two of 
the seven (28.6%) of the low risk and seven of 12 (58%) of the high risk cases 
reached maximum colony numbers after day 14 of culture in response to GM-CSF 
(Fig. 1). No statistical significant differences were found between the different groups. 
Colony numbers formed in response to GM-CSF were identical to normal bone 
marrow in the low risk MDS group and decreased in the high risk group (table 2). 
Kinetics of colony formation in response to Il-3. A low number of myeloid colonies 
were formed following stimulation with 11-3 in normal bone marrow, low and high risk 
MDS (Table 2). However, in case 15 and 19 a large number (105 and 196 per 105 
cells, respectively) of myeloid colonies were formed in response to 11-3, with a 
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Table 2. Time course of colony formation in response to colony 
stimulating factors 
patient Day Numbers of colonies /105 plated cells 
group 
GCT-CM GM-CSF IL-3 
(10% vjv) (10 ngjml) (10ngjml) 
7 114.9 ± 22.3 7.2 ± 3.0 1.3 ± 0.6 
NBM 10 66.9 ± 13.9 17.5 ± 3.8 9.1 ± 3.9 
(n=6) 14 32.7 ± 7.5 39.5 ± 6.8 9.4 ± 2.2 
18 31.8 ± 12.7 24.2 ± 8.5 16.3 ± 5.6 
22 8.7 ± 2.4 24.6 ± 6.1 12.1 ± 3.0 
7 73.0 ± 40.0 12.6 ± 8.8 0.6 ± 0.3 
Low Risk 10 100.8 ± 24.9 31.7 ± 16.5 4.9 ± 1.8 
MDS 14 49.9 ± 12.2 40.5 ± 15.5 11.8 ± 5.0 
(n=7) 18 52.7 ± 21.4 26.6 ± 10.0 13.3 ± 6.6 
22 30.8 ± 10.7 26.4 ± 12.0 14.3 ± 8.4 
7 0.7 ± 0.5 0.9 ± 0.5 0.0 ± 0.0 
High 10 27.3 ± 16.4 3.4 ± 1.6 0.0 ± 0.0 
Risk MDS 14 37.8 ± 9.4 15.7 ± 5.1 15.0 ± 8.4 
(n=12) 18 17.3 ± 4.1 17.3 ± 3.9 16.8 ± 6.9 
22 10.5 ± 3.6 15.8 ± 6.5 16.2 ± 8.6 
maximum number of colonies on day 14 of culture. No apparent differences in colony 
formation kinetics between the different groups were observed. 
Morphology of the colony cells. From separate cultures the morphology of the 
colonies on the day of optimal colony formation were assessed. Therefore liquid-
nitrogen stored bone marrow of three different normal bone marrows and bone 
marrow of cases 1, 4, 8, 9, 18, 21 and 22 were thawed and cultured for the number of 
the days needed for optimal colony growth (as assessed before). Colonies of NBM 
and low risk MDS cultures (cases 1, 4 and 8) consisted of intermediate and terminally 
differentiated cells (myelocytes, metamyelocytes, bands, polymorphonuclear cells, 
monocytes and macrophages ). In all cases monocytes and macrophages were only 
present in GM-CSF stimulated cultures. Basophilic granulocytes were detected in ll-3 
stimulated colonies in normal bone marrow and in cases 18 and 22. 
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Table 3. 
Comparison of the time course of colony formation in 
response to GCT-CM (10% vjv) and rhG-CSF {100 U/ml) 
expressed as percentage of the maximum number of colonies 
formed. 
NBM 
Day GCT-CM 
7 100 
10 74 
14 41 
18 0 
22 0 
a, one normal control. 
b, patient 22. 
G-CSF 
100 
59 
18 
0 
0 
GCT-CM 
0 
84 
100 
nd 
69 
MDS 
G-CSF 
0 
36 
100 
nd 
40 
Blast cell colonies were only observed in two high risk MDS cases (case 21 and 22). 
In these cases the colonies formed after stimulation with either GM-CSF, G-CSF or 
GCT-CM consisted of myeloblasts and promyelocytes (Sudan black positive, a-
naphtylacetate-esterase negative). 
Cytogenetic analysis of the colony cells. In order to determine whether the colonies 
were derived from the abnormal MDS clone, cytogenetic analyses were performed on 
the pooled colony cells of case 4, 7, 21 and 23. No metaphases were obtained in cases 
4 and 7. In case 21, 98% of the 50 metaphases contained the same chromosomal 
abnormality ( 47 XX, Sq-, +21), as had been found in 78% of the metaphases of the 
freshly aspirated bone marrow. In case 23 complex cytogenetic abnormalities were 
found in 62% of the metaphases in the fresh bone marrow, whereas 80% of the 10 
metaphases derived from colony cells showed identical complex abnormalities. 
Colony growth of NBM cells after exposure to 4HC. Figure 2 shows a representative 
example of the growth kinetics of normal bone marrow pretreated with 4-HC for 
depletion of committed progenitors. Colony growth was not observed before day 14 of 
culture. The time sequence of colony growth in response to respectively GCT-CM, 
rhGM-CSF and rhil-3 is identical to nontreated bone marrow, however delayed for 10 
to 14 days. 
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Figure 2. Time course of the colony formation of 4-hydroperoxycyclophosphamide 
pretreated normal bone marrow: A representative example of the colony formation in 
response to GCT-CM (closed circles) GM-CSF (open circles) or Il-3 (triangles) of NBM 
cells after exposure to 4-HC. Symbols represent the number of colonies of triplicate 
cultures (mean ± 1 SEM). 
Identical results were obtained in experiments with bone marrow cells of three other 
normal volunteers; however the day on which colonies were first observed ranged 
from day 10-18. After 22 days of culture, cytological characterization of the colonies 
showed 35 granulocytic colonies following GCT-CM stimulation. After stimulation 
with GM-CSF, two monocytic colonies and 11 blast-colonies were found. The one 
colony that was observed following Il-3 stimulation consisted of blast cells (Table 4). 
Observation of the initial signs of colony formation. In order to determine whether 
the delay in colony formation in MDS is caused by either a delay in the initiation of 
the mitotic cycle of progenitor cells or by a increase in cycling time of the colony cells 
we performed an additional experiment with one normal control, one low risk MDS 
(RA, case 2) and two high risk patients (RAEB: case 10 and RAEBt: case 11). Daily 
inspection of cultures stimulated with GCT-CM showed cluster growth from day 4 
onwards in NBM and the low-risk MDS case (Fig.3, upper panels). In the high risk 
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Table 4. Nature of colony formation by 4HC pretreated 
normal bone marrow cells on day 22 of culture 
type of 
colony 
CFU-G 
CFU-M 
CFU-GM 
CFU-blast 
number of colonies/ 105 plated cells 
GCT-CM 
(10% vjv) 
35 
0 
0 
0 
GM-CSF 
(10 ngjml) 
0 
2 
0 
11 
Il-3 
(10 ngjml) 
0 
0 
0 
1 
cases the first signs of cluster formation was observed on days 6 and 7 (Fig. 3, lower 
panels). When the number of colonies increased the number of clusters decreased, 
indicating that clusters rapidly grew to colonies. 
DISCUSSION 
The data presented here show that in MDS, colony formation of myeloid progenitor 
cells is delayed during and in parallel with the disease progression. The delay is less 
pronounced in the low risk MDS group as compared with the high risk MDS group. 
Differences in the kinetics of colony formation between the low and high risk MDS 
groups were more apparent following stimulation with GCT-CM than with GM-CSF 
or Il-3. GCT-CM was found to stimulate primarily the formation of granulocytic 
colonies. Recombinant G-CSF induced the formation of identical colonies with the 
same growth kinetics in both normal bone marrow and MDS as GCT-CM, indicating 
that the effects of GCT-CM may be primarily due to the colony stimulating activity of 
G-CSF. Since the granulocyte progenitor cell is a relative mature colony forming cell 
it appears that during progression of MDS the late progenitor cells are more affected 
than the more early progenitors, such as the CFU-GMs. 
Disease progression in MDS may be due to the gradual clonal expansion of the 
abnormal population, with suppression of normal haemopoiesis. 
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Figure 3. Time course of cluster and colony formation in response to GCT-CM Cluster 
(more than 8 cells, closed circles) and colony (more than 50 cells, open circles) formation 
of one normal bone marrow (upper left panel:NBM), one low risk MDS patient (upper 
right panel:RA, case 2), and two high risk patients (lower left panel: RAEB, case 10) 
lower right panel: RAEBt, case 11 ). Points represent the mean of triplicate cultures. 
It has been demonstrated by Abkowitz et al., that when this occurs both erythroid and 
granulocyte-macrophage colonies appear to be derived from the abnormal clone (12). 
In our study cytogenetic analyses performed on the colonies of two cases revealed the 
presence of a chromosomal abnormalities typical for the MDS clone, even in a higher 
frequency than found in the fresh bone marrow. In these cases a delayed colony 
formation was observed, indicating that this growth pattern is a characteristic of the 
abnormal clone. Moreover, recently published results on clonal analysis using 
recombinant DNA techniques established a clonal origin of the vast majority of the 
periferal blood and bone marrow cells in almost every MDS patient analyzed (1,13). 
The suppressed normal hemopoiesis appears to regain its place only after eradication 
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of the MDS clone by chemotherapy or differentiation induction therapy (14). Taken 
together, it seems to be likely that the observed delay in colony formation is specific 
for the abnormal clone in MDS. 
Early progenitor cells are considered to be dormant, i.e., in G0 of the cell cycle, 
whereas the more mature progenitor cells are relatively more frequently in active 
cycle (15). Doubling times of murine committed (late) progenitor cells are reported to 
be shorter than the doubling times of pluripotent (early) progenitor cells (7). This 
would imply that the observed delay in colony formation in MDS may be explained by 
a relative increment of early progenitor cells (left shift) as is also suggested by Haak 
et al. (16). However, in this study the delay in colony formation was not associated 
with a relative increase of the GM-CSF responsive compartment, as would be 
expected in case of a relative enlargement of the earlier compartments. Baines et al. 
(17) have reported that the colony formation of purified CD34 positive cells in MDS 
is even decreased as compared to that of CD34 positive normal bone marrow cells. 
These findings do not support the concept of a left shift in the progenitor cell 
compartment as an explanation for altered kinetics of colony formation in MDS. 
The presence of a functional defect of the progenitor cells may be another explana-
tion. Tsuda et al. (8) have described that only the early G1 phase of cell cycle is 
permissive for the stimulation with colony stimulating factors. In this concept an 
increment of dormant cells in the late progenitor cell compartment would result in a 
relative decrease of growth factor responsive cells. There is considerable experimental 
evidence that the majority of the hemopoietic stem cells reside in resting state of cell 
cycle (7,15). Since it is reported that primitive progenitor cells will be spared during 
in vitro 4-HC treatment (18, 19,20), exposure of bone marrow cells to 4-HC will conse-
quently result in a relative enrichment for non-cycling progenitor cells. Exposure of 
normal bone marrow cells to 4-HC resulted in the absence of colony formation before 
day 14 of culture upon stimulation with GCT-CM. In addition, no clusters could be 
detected before day 7. These findings indicate that all the actively cycling progenitor 
cells in the bone marrow are depleted by the 4-HC exposure. Maximum numbers of 
colonies were observed in an identical sequence as in unexposed bone marrow, i.e., 
first after GCT-CM followed by GM-CSF and 11-3. The delay in colony growth 
indicates that neither GCT-CM (G-CSF), nor GM-CSF or 11-3 triggers dormant cells 
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into cell cycle but rather exert their effects after the cells have initiated to cycle. 
Furthermore, in an additional experiment, daily inspection of untreated cultures 
showed that in MDS the initial signs of cluster formation were observed later as 
compared to NBM. In NBM, clusters could already be detected on day 4 of culture, 
whereas in some MDS cases no sign of growth was observed before day 6 of culture. 
An increase in colony numbers was accompanied by a decrease in the number of 
clusters, indicating that clusters rapidly grew to colonies. These results indicate that 
the observed delay in colony formation in MDS is caused by a greater time-lag before 
MDS progenitors start to cycle, rather than being the result of a increased cycling 
time of the colony cells. A prolongation of the time spend in G0 by MDS progenitor 
cells, may therefore be the most likely explanation for the observed delay in colony 
formation. 
Recent reports indicate that IL-1 and IL-6 may act as co-stimulants for the growth of 
normal primitive hemopoietic progenitor cells (22,23) as well as for leukemic blast-
cell progenitors (24). Since our results suggest that the growth factors used in this 
present study are unable to effectively recruit MDS progenitor cells into cell cycle on 
their own, combinations with co-stimulants are probably needed to accomplish this. 
Our findings may have implications for the understanding of the pathogenesis of MDS 
as well as for the application of growth-factor therapy either alone or in combination 
with chemotherapy in MDS. 
REFERENCES 
1. Janssen JWG, Buschle M, Layton M, Drexler HG, Lyous J, Van den Berghe H, Heimpel H, 
Kubanek B, Kleihauer E, Mufti GJ, Bartram CR. Clonal Analysis of Myelodysplastic Syn-
dromes: evidence of multipotential stem cell origin . Blood 1989; 73: 243-254. 
2. Verma DS, Spitzer G, Dicke KA, McCredie KB. In vitro agar culture patterns in preleukemia 
and their clinical significance. Leuk Res 1979;3:41-49. 
3. Partanen S, Juvonen E, Ruutu T. In vitro culture of hemopoietic progenitors in myelodysplastic 
syndromes. Scand J Haematol1986; 36 (suppl 45): 98-101. 
4. Schipperus MR, Hagemeijer A, Ploemacher RE, Lindemans J, Voerman JSA, Abels J. In 
myelodysplastic syndromes progression to leukemia is directly related to PHA dependency for 
colony formation and independent of in vitro maturation capacity. Leukemia 1988;2:433-437. 
87 
5. Mayami H, Baines P, Bowen DT, Jacobs A. In vitro growth of myeloid and erythroid progenitor 
cells from myelodysplastic patients in response to recombinant human granulocyte-macrophage 
colony-stimulating factor. Leukemia 1989;3:29-32. 
6. Francis GE, Bol S, Berney JJ. Proliferative capacity, sensitivity to colony stimulating activity and 
buoyant density: linked properties of granulocyte-macrophage progenitors from normal human 
bone marrow. Leuk Res 1981;5: 243-250. 
7. Suda T, Suda J, Ogawa M. Proliferative kinetics and differentiation of murine blast cell colonies 
in culture: evidence for variable G0 periods and constant doubling rates of early pluripotent 
hemopoietic progenitors. J Cell Physiol 1983;117: 308-318. 
8. Tsuda H, Neckers IM, Pluznik DH. Colony stimulating factor induced differentiation of murine 
M1 myeloid leukemia cells is permissive in early G1 phase. Proc Natl Acad Sci USA 
1986;83:4317-4321. 
9. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C. 
Proposals for the classification of the myelodysplastic syndromes. Brit J Haematol 1982;51:189-
199. 
10. Hagemeijer A, Smit EM, Bootsma D. Improved identification of chromosomes of leukemic cells 
in methotrexaat treated cultures. Cytogenet Cell Genet 1979;23:208-212. 
11. Hamden DG and Klinger HP (eds). ISCN (1985): an international system for human cytogenetic 
nomenclature. Published in collaboration with Cytogenet Cell Genet. Basel: Karger, 1985. 
12. Abkowitz JL, Fialkow PJ, Niebrngge DJ, Raskind WH, Anderson JW. Pancytopenia as clonal 
disorder of a multipotent haemopoietic stem cell. J Clin Invest. 1984;73:258-261. 
13. Lyons J, Janssen JW, Bartram C, Layton M, Mufti GJ. Mutation of Ki-ras and N-ras oncogenes 
in myelodysplastic syndromes. Blood 1988;71:1707-1712. 
14. Layton DM, Mufti GJ, Lyons J, Janssen JW, Bartram CR. Loss of ras oncogene mutation in a 
myelodysplastic syndrome after low-dose cytarabinetherapy. N Engl J Med. 1988; 318: 1468-1469. 
15. Lathja LG. Stem cell concepts. Differentiation 1979;14:23-28 
16. Haak HL, Kerkhofs H, van der Linden JS, Schonewille H, van der Sanden-van der Meer, 
Hermans J. Significance of in vitro cultures in myelodysplastic syndromes. Scand J Haematol. 
1986;37:380-389. 
17. Baines P, Mayani H, Baines M, Hoy T, Jacobs A. Eurichment of CD34 (My10) positive 
haemopoietic cells from normal and myelodysplastic human marrow (abstr). Factors and Vectors 
in Haemopoiesis, ZWO/TNO/NlH symposium The Hague: The Netherlands, 1988. 
18. Komatsu N, Suda T, Suda J, Miura Y. Survival of highly proliferative colony-forming cells after 
treatment of bone marrow cells with 4-hydroperoxycyclophosphamide. Cancer Res.1987;47:6371-
6376. 
88 
19. De Jong JP, Nikkels PGJ, Brockbank KGM, Ploemacher RE, Voerman JSA. Comparative in 
vitro effects of cyclophosphamide derivates on murine bone marrow-derived stromal and 
hemopoietic progenitor cell classes. Cancer Res.1985; 45:4001-4005. 
20. Siena S, Castro-Malaspina H, Gulati S, Li Lu, Colvin MO, Clarkson B, O'Rielly RJ, Moore 
MAS. Effects of in vitro purging with 4-hydroperoxycyclophosphamide on the hematopoeitic and 
microenviremental elements of human bone marrow. Blood 1985;65:655-662. 
21. Moore MAS, Warren DJ. Synergy of interleukin 1 and granulocyte colony-stimulating factor: in 
vivo stimulation of stem-cell recovery and hematopoietic regeneration following 5-fluorouracil 
treatment of mice. Proc Nat! Sci USA 1987; 84:7134-7138. 
22. Leary AG, lkebuchi K, Hirai Y, Wong GG, Yang YC, Clark SC. Synergism between interleukin-
6 and interleukin-3 in supporting proliferation of human hematopoietic stem cells: comparison 
with interleukin 1a. Blood 1988;6:1759-1763. 
23. Haman THA, Goncalves 0, Wong GG, Clark SC. Interleukin-6 enhances growth factor-
dependent proliferation of the blast cells of acute myeloblastic leukemia. Blood;1988;2:823-826. 
24. Hoang T, Haman A, Goncalves 0, Letendie F, Mathieu M, Wong GG, ClarkS. Interleukin 1 
enhances growth-factor dependent proliferation of the clonogenic cells in acute myeloblastic 
leukemia and of normal human primitive progenitors. J Exp Med 1988;168:413-474. 
89 
90 
CHAPTER 5 
THE COMBINED EFFECTS OF IL-3, GM-CSF AND G-CSF ON THE IN VITRO 
GROWTH OF MYELODYSPLASTIC MYELOID PROGENITOR CELLS 
Martin R. Schipperus, Pieter Sonneveld, Jan Lindemans, Nel Vink, Margreet 
Vlastuin, Anne Hagemeijer, Johannes Abels 
Department of Hematology and Cell Biology and Genetics, Erasmus University and 
University Hospital Dijkzigt Rotterdam, The Netherlands 
Published in Leukemia Research, 1990; 14: 1019 - 1025. 
91 
ABSTRACT 
The decreased or absent in vitro colony formation in response to single recombinant 
hematopoietic growth factors has been reported previously. Here we report on the 
effects of the combination of Interleukin-3 (Il-3), granulocyte-macrophage colony-
stimulating factor (GM-CSF) and granulocyte-CSF (G-CSF) and the effect of the 
conditioned medium of the giant tumor cell line (GCT-CM) on the proliferation of 
myelodysplastic (MDS) marrow myeloid progenitor cells and normal bone marrow 
(NBM) controls. Colony growth was most effectively sustained by GCT-CM and G-
CSF in normal bone marrow (NBM) cultures. GM-CSF and IL-3 were less effective 
in inducing myeloid granulocytic colony growth, whereas the effects of Il-3 and GM-
CSF were found to be approximately additive. The number of NBM granulocytic 
colonies induced by G-CSF and GCT-CM stimulation were comparable, whereas this 
granulocyte colony stimulating activity could be neutralized by anti-G-CSF antibodies. 
In addition GCT-CM was found to contain burst promoting activity, which could be 
neutralized by anti-Il-3 antibodies. Il-3 did not enhance the G-CSF activity in NBM 
cultures. No additive effect of stimulation with the combination of Il-3 and GM-CSF 
was observed in MDS marrow cultures, suggesting that these growth factors act on an 
identical progenitor cell population in MDS. G-CSF stimulated the growth of sig-
nificantly lower colony numbers than GCT-CM, in contrast to NBM cultures. The 
decreased granulocytic colony formation of MDS marrow cells could clearly be 
enhanced by co-stimulation with Il-3. These results suggest that MDS myeloid 
progenitor cells require the exposure to both a pluripotent colony stimulating factor, 
like Il-3, and a lineage specific factor, like G-CSF, for optimal proliferation. 
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INTRODUCTION 
The myelodysplastic syndrome (MDS) is a clonal disorder of the multipotential stem 
cell (1) characterized by refractory cytopenia and qualitative and quantitative 
abnormalities of one or more cell lineages in the bone marrow. Up to 40% of the 
patients with MDS eventually develop an acute myeloblastic leukaemia (AML) (2). 
The decreased in vitro colony forming capacities of the MDS bone marrow progeni-
tor cells are extensively described (3-6). In all these studies colony formation was 
stimulated by crude sources of colony stimulating activity (CSA). The recent availabi-
lity of recombinant human colony-stimulating factors (CSF) made it possible to 
investigate the regulation of normal (7,8) and leukaemic haemopoiesis in vitro (9,10). 
Limited information exists, however, on the responsiveness of MDS colony forming 
cells for the recombinant CSF. Recently Mayani et al.(ll) found subnormal myeloid 
colony numbers in response to GM-CSF at concentrations shown to be optimal for 
colony formation in cultures of normal bone marrow, but supersaturating concentra-
tions of GM-CSF were observed to be able to enhance the myeloid colony formation 
of many MDS marrows. Carlo-Stella et al. (12) have also reported a decreased 
myeloid colony growth in response to GM-CSF in a majority of the fractionated, 
accessory cell depleted MDS marrows. However, no effect of high doses of GM-CSF 
was observed. Since Il-3 and GM-CSF have been reported to recruit monocytes to 
express and secrete G-CSF (13), the effect of high GM-CSF doses found by Mayani 
et al. may be indirect. 
We have recently found that the conditioned medium of the giant tumor cell line 
(GCT-CM), produced in our laboratory, stimulates predominantly granulocytic colony 
formation, whereas the growth of MDS bone marrow derived CFU-G was more 
effectively sustained than by single recombinant growth factors (14). Since GCT-CM 
contains various haematopoietic growth factors this effect may be due to additive or 
synergistic effects of these factors. Although, additive and synergistic effects of 
combinations of growth factors on leukemic blast cells (15) and normal multipotential 
haematopoietic progenitors (16) have been reported, their effect on MDS progenitor 
cells has not been addressed. 
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The aim of the present study was therefore to compare the colony stimulating activity 
of GCT-CM with the effects of recombinant human Il-3, GM-CSF and G-CSF, either 
alone or in combination, on MDS marrow myeloid progenitor cells. 
MATERIALS AND METHODS 
Normal donors 
Normal marrow samples were obtained from five healthy volunteers posterior iliac 
crest puncture. The marrow was collected in glass tubes containing Hanks/Hepes with 
preservative-free heparin. 
Patients 
Seventeen patients with MDS (2 RA, 2 RARS, 6 RAEB, 4 RAEBt and 3 CMML) 
and 5 patients with leukemic transformation of MDS (LT-MDS) were studied with 
informed consent. The MDS cases were classified according the F AB nomenclature 
(17). 
Preparation of cell suspensions 
Low-density bone marrow cells of patients and normal donors were obtained by 
Ficoll-lsopaque centrifugation (1.077 gjml, 1000 g, 20 min). T-cell depletion was 
performed by rosette formation with 2-aminoisothiouroniumbromide (AET, Sigma) 
treated sheep erythrocytes and subsequent ficoll separation. In addition adherent cells 
were removed by incubating the cell suspension (1 x 106/ml in a-DMEM with 10% 
Fetal Calf Serum (FCS)) for 1 hour at 37°C, 5% C02 in a fully humidified atmosphe-
re. Non-adherent cells were collected and washed twice in HanksjHepes. 
Recombinant human colony stimulating factors and interleukins 
Recombinant granulocyte-macrophage colony stimulating factor (rh-GM-CSF) was 
prepared and generously made available by Schering (Kenilworth, New Yersey, USA) 
and was used in a concentration of 10 ngjml. Recombinant granulocyte colony-
stimulating factor (G-CSF) was purchased from Genzyme (Boston, MA, USA) and 
was used at 100 U /ml. The preparation of recombinant Interleukin-3 (11-3), a 
generous gift from Dr. G. Wagemaker (Erasmus University Rotterdam) (18) and 
produced by Gist-Brocades (Rijswijk). 11-3 was used at a concentration of 10 ng/ml. 
Recombinant human erythropoietin (Boehringer, Mannheim F.R.G.) was used in a 
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concentration of 2 U /mi. All applied concentrations of colony stimulating factors 
were optimal concentrations, as determined by dose-response studies using clonogenic 
assays on normal low-density, T-cell depleted, non-adherent bone marrow cells. 
Giant Cell Tumor Conditioned Medium (GCT-CM) 
GCf-CM was prepared by culturing the confluent growing cell-line (obtained from 
the American Type Culture Collection, ATCC TIB 223) for 7 days in a-DMEM with 
10% FCS (10ml per 75 cm3) and was used as a source of colony stimulating activity at 
a concentration of 10% v jv. 
Antibodies directed against G-CSF and 11-3 
Polyclonal rabbit anti-human granulocyte-CSF was purchased from Genzyme (Boston, 
MA, USA). A concentration of 10 ng/ml neutralizes the bioactivity expressed by 
approximately 100 units of G-CSF. Polyclonal rabbit anti-human interleukin-3 
antibody was purchased from Genzyme. Approximately 1 p.g neutralizes 200 pg of 
human Il-3. Neutralization experiments were performed by incubating different con-
centrations of the antibody with an equal volume of GCT-CM or 100 U /ml G-CSF or 
10 ng/ml IL-3 for 1 h at 37°C. 
Colony assay 
Cultures were performed in the a-modification of Dulbecco's modified Eagles 
Medium (a-DMEM, Flow) containing 0.9% methylcellulose (Fluka Methocell MC), 
and supplemented with 20% FCS and 1% dialyzed Bovine Serum Albumin (BSA), 30 
p.M lecithine, 0.1 p.M fully iron-saturated human transferrin, 100 p.M mercaptoethanol. 
Cultures were performed in 24 wells plates (Costar), 250 p.l per well containing 2.5 x 
104 bone marrow cells. The cultures were incubated at 37 oc in a fully humidified 
atmosphere of 5% C02 in air. Myeloid colonies (more than 50 cells) were counted on 
day 7 - 10 for the granulocyte colony forming unit (CFU-G),and day 14 - 18 for the 
granulocyte-macrophage CFU (CFU-GM). Erythroid colonies were counted on day 7 
(CFU-E) and erythroid bursts on day 14 (BFU-E). Of some cultures colonies were 
picked from a well for staining with the May-Grunwald-Giemsa technique and subse-
quent morphological examination. 
Statistical analysis 
Data were statistically evaluated with the Wilcoxon's signed-ranks test for two groups. 
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The effect of cxll-3 and cxG-CSF on the activities of GCT-CM 
Since GCT-CM was found to stimulate both granulocytic and erythroid colony 
formation, we investigated as to wether the granulocyte-colony stimulating activity ( G-
CSA) and the burst promoting activity (BPA) could be neutralized by antibodies 
directed against G-CSF and Il-3, respectively. Whereas, the G-CSA present in GCf-
CM could be neutralized anti-G-CSF antibodies (Fig.1), the BPA present in GCf-CM 
could be neutralized by anti-Il-3 antibodies (Fig. 2). cxll-3 had no effect on either 
GCf-CM or GM-CSF induced myeloid colony formation and cxG-CSF had no effect 
on the GCf-CM induced BFU-E formation of normal bone marrow (data not 
shown). 
Effect of GCT-CM, Il-3 and GM-CSF on MDS bone marrow cultures 
The effect of stimulation on myeloid colony growth by fractionated, accessory cell 
depleted, MDS bone marrow with GCf-CM, GM-CSF and Il-3 is shown in Table 2. 
As in normal bone marrow cultures GCT-CM was found to stimulate predominantly 
granulocytic colonies. GM-CSF and 11-3 either alone or in combination, were sig-
nificantly less effective (p <0.01) in inducing myeloid colony formation than GCf-CM. 
In two cases, however (cases 8 and 17), high numbers of myeloid colonies were 
formed in response to 11-3 (i.e 105.2 and 196.0 respectively). The effect of stimulation 
of MDS bone marrow cultures with the combination of GM-CSF and Il-3 was less 
than additive in thirteen, additive in one and more than additive in two of the sixteen 
cases. 
As described above, in most MDS cases neither GM-CSF nor Il-3 nor their combina-
tion were found to be more effective than GCT-CM in stimulating the proliferation of 
myeloid progenitor cells. However, in case 5 GM-CSF, in cases 8 and 12 Il-3 and in 
case 18 the combination of 11-3 and GM-CSF induced the formation of more colonies 
than GCf-CM. 
Effects of II-3 and G-CSF in MDS bone marrow cultures 
In contrast to NBM cultures, in MDS marrows G-CSF was less effective in inducing 
the growth of granulocytic colonies than GCf-CM (Table 3). However, Il-3 could 
clearly enhance the G-CSF effect in three of the four cases tested. The effect was 
more than additive in three cases and additive in one. In the former three cases the 
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Table 2, MDS marrow myeloid colony formation in 
response to GCT-CM, GM-CSF, I1-3 and the 
combination of GM-CSF with Il-3. 
1. RA* 
2. RA 
3. RARS 
4. RARS 
5. RAEB 
6. RAEB 
7. RAEB 
8. RAEB 
9. RAEB 
10. RAEB 
11. RAEBt 
12. RAEBt 
13. RAEBt 
14. RAEBt 
15. CMML 
16. CMML 
17. CMML 
18. LTMDs+ 
19. LTMDS 
20. LTMDS 
21. LTMDS 
22. LTMDS 
23. LTMDS 
Mean 
SEM 
GCT-CM 
192.0 
106.8 
82.8 
316.0 
21.2 
20.0 
102.8 
72.0 
64.0 
132.0 
76.0 
53.2 
94.8 
25.2 
14.8 
164.0 
304.0 
26.0 
61.2 
14.8 
2.8 
78.0 
15.0 
88.7 
18.3 
GM-CSF 
46.8 
5.2 
30.8 
133.2 
74.0 
0.0 
18.8 
16.0 
42.8 
26.8 
5.2 
65.2 
8.0 
n.d. 
0.0 
82.0 
138.0 
14.0 
38.4 
6.8 
4.0 
14.0 
n.d. 
36.7 
8.5 
Il-3 
14.8 
2.8 
34.8 
n.d. 3 
44.0 
0.0 
n.d. 
105.2 
n.d. 
54.0 
9.2 
66.0 
4.0 
n.d. 
4.8 
n.d. 
196.0 
18.0 
14.8 
8.0 
1.2 
0.0 
n.d 
31.9 
11.9 
GM-CSF 
+ 
Il-3 
16.0 
0.0 
40.0 
125.2 
77.2 
0.0 
12.0 
100.0 
46.8 
45.6 
14.4 
70.0 
9.2 
n.d. 
4.0 
44.0 
160.0 
48.0 
44.0 
13.2 
1.2 
18.8 
n.d 
42.4 
9.5 
* MDS-subtype according to the FAB classification. 
+ LT-MDS: leukemic transformed MDS. 
n.d. not determined 
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number of colonies formed in response to G-CSF and IL-3 was comparable to the 
number of colonies formed in response to GCf-CM. In two of these four cases 
erythroid burst formation was found in response to either GCT-CM or ll-3, although 
only a few burst were formed in these two cases. No effect of the addition of G-CSF 
to Il-3 was observed on the erythroid burst formation in MDS bone marrow cultures. 
Cytogenetic analysis of the colony cells: 
In order to determine whether the colonies were derived from the abnormal MDS 
clone, cytogenetic analyses were performed on the pooled colony cells of case 3, 9, 10 
and 23. No metaphases were obtained in cases 3 and 9. In case 10, 98% of the 50 
metaphases contained the same chromosomal abnormality ( 47 XX, 5q-, +21), as had 
been found in 78% of the metaphases of the fresh bone marrow. In case 23, a patient 
with leukaemic stage of a trilineage MDS, complex cytogenetic abnormalities were 
found in 62% of the metaphases in the fresh bone marrow, whereas 80% of the 10 
metaphases derived from colony cells showed identical complex abnormalities. 
Table 3, Myeloid colony (CFU-G) and erythroid burst (BFU-E) 
formation in response to GCT-CM, G-CSF, Il-3 and G-CSF with Il-3 
of MDS bone ma=ow. 
case 
GCT-CM 
G-CSF 
Il-3 
Il-3 
+ 
G-CSF 
10 11 
101.0 69.0 
30.0 9.2 
28.6 8.4 
106.7 18.7 
CFU-G* 
13 
26.8 
12.0 
2.0 
34.8 
BFU-E* 
14 10 11 13 14 
25.2 0.0 10.7 12.0 0.0 
o.o n.d. n.d. n.d. n.d. 
5.2 0.0 7.0 3.7 0.0 
20.0 0.0 6.7 2.8 0.0 
* Each value represent the mean of triplicate cultures performed 
wi'C:h low-density, non-adherent, T-cell depleted bone marrow 
cells. 
n.d. not determined. 
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DISCUSSION 
In this study we investigated the response patterns of haematopoietic progenitor cells 
derived from bone marrow of patients with a myelodysplastic syndrome stimulated 
with various recombinant human colony stimulating factors and GCT-CM. In 
particular we addressed the question whether combinations of colony stimulating 
factors were necessary for optimal proliferation of myeloid progenitor cells in MDS. 
In normal bone marrow cultures the effect of the combination of GM-CSF and Il-3 
rendered more colonies than each factor alone, suggesting that their activities are 
partially overlapping. This is in agreement with previous data indicating that Il-3 and 
GM-CSF stimulate overlapping but distinct progenitor cell populations (19,20). As we 
have also reported previously (14) GCT-CM was found to stimulate primarily the 
formation of granulocytic colonies. GM-CSF but not GCT-CM was found to stimulate 
the growth of mixed granulocyte/macrophage colonies. GCT-CM and G-CSF 
induced comparable numbers of colonies and the colonies were identically granulocy-
tic of nature. Moreover, the granulocytic colony stimulating activity present in GCT-
CM was neutralized by antibodies directed against G-CSF. These results indicate that 
GCT-CM contains G-CSF as a major source of colony stimulating activity. In 
addition, GCT-CM was found to contain BPA as well, which could be neutralized by 
anti-IL-3 antibodies, indicating that the BPA in GCT-CM could be assigned to Il-3. 
The combination of G-CSF and Il-3 did not render more myeloid colonies than G-
CSF alone or more erythroid bursts than Il-3 alone, indicating distinct activities of Il-3 
and G-CSF on normal bone marrow progenitor cells. Cytogenetic analyses performed 
on the colonies of two MDS cases revealed the presence of chromosomal abnormali-
ties typical for the MDS clone, even in a higher frequency than found in the fresh 
bone marrow, indicating that the colonies are derived from the abnormal clone. 
Apparently the abnormal clone rather than the residual normal haemopoiesis is 
stimulated by haemopoietic growth factors in MDS. These findings can be explained 
by the fact that disease progression in MDS is due to the gradual clonal expansion of 
the abnormal population, with suppression of the normal haemopoiesis, which is 
demonstrated by the findings of Abkowitz et a1.(21), that both erythroid and granulo-
cyte-macrophage colonies appear to be derived from the abnormal clone. More recent 
reports, presenting data on X-linked restriction fragment length poly-morphisms, 
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provide evidence that MDS is a clonal disorder of the pluripotent haemopoietic stem 
cell (1,22), which clone has totally replaced the normal haemopoiesis. Stimulation of 
the abnormal clone by haemopoietic growth factors is also observed in vivo (23,24). 
The residual normal haemopoiesis, however, appears to regain its place after 
eradication of the MDS clone by chemotherapy or differentiation induction therapy 
(25), and may then be preferentially stimulated by haemopoietic growth factors (26). 
In myelodysplastic bone marrow cultures GM-CSF and ll-3 were significantly less 
effective in inducing myeloid colony formation than GCf-CM. Only in three of the 
sixteen cases the effect of the combination of ll-3 and GM-CSF was found to be 
additive or more than additive, whereas in one of those cases more colonies were 
formed than with GCT-CM. Therefore, our results suggest that the activities of 11-3 
and GM-CSF on MDS myeloid progenitor cells are more overlapping than in NBM 
cultures, which suggests that their target cell populations are largely identical. 
Whereas in NBM cultures G-CSF and GCT-CM contained comparable colony 
stimulating activities, in MDS bone marrow G-CSF did induce a significantly lower 
number of myeloid colonies than GCf-CM. Since we had previously found that GCf-
CM contains ll-3 apart from G-CSF, it appears likely to presume that the combina-
tion of these two factors were responsible for the larger number of colonies formed in 
response to GCf -CM. In three of the four MDS cases tested we could indeed 
demonstrate a synergistic and in the other case an additive effect of the combination 
of IL-3 and G-CSF on the growth of myeloid colonies. In the former three cases the 
effect of co-stimulation with 11-3 and G-CSF was comparable with the effect of GCf-
CM, whereas in the latter case GCf-CM was more effective in stimulating MDS 
progenitor cells. Therefore, it can not be excluded that factors distinct from 11-3 and 
G-CSF contribute to the potent colony stimulating activity of GCf-CM on MDS bone 
marrow. Still, it appears that a subset of granulocytic colony forming cells require 
both 11-3 and G-CSF for optimal colony formation, suggesting that a pluripoietin 
should be combined with a later-acting factor for optimal effect, which is a charac-
teristic shared by early bone marrow progenitor cells and peripheral blood progenitor 
cells (27). Some of the effects of 11-3, however, may be indirect, i.e., mediated by 
residual accessory cells, although all the bone marrows were thoroughly depleted of 
adherent and T-cells and the dose dependent inhibition of colony formation by al1-3 
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suggests a direct action of Il-3. However, to obtain conclusive evidence a larger series 
of experiments studying the effect the combination of Il-3 and G-CSF and GM-CSF 
and G-CSF on myeloid colony growth in MDS is required. 
We conclude that the activities of Il-3 and GM-CSF on myeloid progenitor cells 
present in MDS bone-marrows are more overlapping than in NBM cultures. Conco-
mitantly the results obtained in a small series of MDS patients suggest that the 
majority of MDS progenitor cells are not yet responsive for G-CSF. The synergistic 
effect of the combination of Il-3 and G-CSF may suggest that these progenitor cells 
require exposure to a pluripoietin like Il-3 in order to acquire responsiveness for the 
later-acting factor G-CSF. 
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SUMMARY 
Interleukin-1 (Il-l) and Interleukin-6 (Il-6) have been reported to enhance the growth 
factor dependent colony formation of normal primitive haematopoietic progenitor 
cells as well as of leukemic blast-cell progenitors. We investigated the effects of 11-lB 
and 11-6 in combination with Granulocyte-Macrophage Colony-Stimulating factor 
(GM-CSF) on the in vitro colony formation of myeloid progenitors from 23 patients 
with a Myelodysplastic syndrome (MDS). Neither 11-18 nor 11-6 were found to have 
colony stimulating activity on their own. In normal bone marrow cultures, either 
stimulated with optimal or sub-optimal doses of GM-CSF, no enhancing or antagonis-
tic effect of 11-6 or 11-18 was detected. In a majority of the MDS cases, however, an 
enhancing effect of 11-6 and 11-lB in combination with GM-CSF was observed (20 out 
of 23 and 10 of the 21 cases respectively). In 3 cases of the 11-6 and GM-CSF 
combination an antagonistic effect was observed as well as in 4 cases of the 11-18 and 
GM-CSF combination. A delayed addition of 11-6 to the cultures did not result in an 
abrogation of the effect, indicating that 11-6 is not required immediately at the 
initiation of the culture. These results indicate that co-stimulation with IL-6 or IL-lB 
is able to augment the GM-CSF activity on MDS myeloid progenitor cells. 
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INTRODUCTION 
The rnyelodysplastic syndrome (MDS) comprises a group of acquired disorders, which 
are characterized by an ineffective haernopoiesis resulting in a cytopenia of one or 
more cell lineages (Koeffler, 1986; Mufti & Galton,1986). Cytogenetic and G-6-PD 
studies have demonstrated that MDS is a clonal disease of the haernopoietic stern cell 
(Fialkow et al, 1981; Raskind et al, 1984; Janssen et al, 1989). Its high mortality rate 
results from the complications associated with persistent cytopenias, as well as from 
transformation to leukaemia. The abnormal haernopoiesis is reflected in an abnormal 
in vitro growth pattern of MDS bone marrow (Verma et al, 1979; Partanen et 
al, 1986). Decreased or absent megakaryocyte and erythroid colony formation is a 
typical finding in MDS (Juvonen et al, 1989). An abnormal granulocyte-macrophage 
colony formation may have prognostic value (Juvonen et al,1989; Haak et al,1986; 
Schipperus et al,1988). The nature, however, of the aberrant colony formation is 
poorly understood. The recent cloning of genes of various haernopoietic growth 
factors (Clark & Kaman, 1987; Sieff,1987), generally referred to as colony stimulating 
factors (CSF) or interleukins, has made it possible to produce purified CSF in large 
quantity and to investigate their in vitro and in vivo effects in MDS. The first clinical 
trials on the effects of recombinant CSF in MDS are being performed already 
(Vadhan-Raj et al, 1987; Antin et al, 1988; Ganser et al,1989). However, there is still 
limited information on the effect of recombinant haernopoietic growth factors on 
MDS in vitro colony formation. Recent reports indicate that the MDS progenitor cells 
defective response to growth factors is not affected by manipulation of recombinant 
factor levels or combinations (Baines et al, 1990). Carlo-Stella et al (1989) have 
reported that GM-CSF (even in high concentrations) is unable to improve the 
abnormal in-vitro colony formation of bone-marrow cells depleted of accessory cells. 
However, Mayani et al (1989), using unfractionated bone marrow, found that super-
saturating concentrations of GM-CSF could ameliorate the abnormal colony formati-
on. These discordant results may be due to an indirect effect of GM-CSF: the release 
of additional factors by rnonocytes and rnacrophages (Metcalf & Nicola, 1985; Warren 
& Ralph, 1986), which enhance the GM-CSF dependent colony formation of MDS 
myeloid progenitor cells. Apart from their activities on the lymphoid lineage, Il-l and 
the pleiotropic cytokine Il-6 have been reported to act as co-stimulants for the growth 
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of normal primitive haematopoietic progenitors (Moore et al,1987; Leary et al,1988) 
as well as for leukemic blast-cell progenitors (Hoang et al 1988a,b). ll-6 has also been 
implicated as a co-stimulant in the late stages of neutrophilic differentiation (Caracci-
olo et al, 1989a, b). The effects of Il-6 and IL-l on MDS marrow, however, have not 
been reported so far. The aim of the present study is to investigate whether ll-6 and 
11-lB are able to enhance the in-vitro GM-CSF dependent colony formation of MDS 
progenitor cells. 
MATERIALS AND METHODS 
Normal donors. Normal marrow samples were obtained from posterior ilieac crest 
puncture of five healthy volunteers. The marrow was collected in glass tubes contai-
ning Hanks/Hepes with preservative-free heparin. 
Patients. 18 patients with MDS (two RA,two RARS, seven RAEB, four RAEBt and 
three CMML) and five patients with leukaemic transformation of MDS (LT-MDS) 
were studied upon informed consent. The MDS cases were classified according to the 
FAB nomenclature (Bennett et al, 1982). 
Preparation of cell suspensions. Low-density bone marrow cells of patients and 
normal donors were obtained by Ficoll-Isopaque centrifugation (1.077 gjml, 1000 g, 
20 min). T-cell depletion was performed by rosette formation with 2-aminoisothiouro-
niumbromide (AET, Sigma) treated sheep erythrocytes and subsequent ficoll separati-
on. Adherent cells were removed by incubating the cell suspension (1 x 106/ml in a-
DMEM with 10% fetal calf serum (FCS)) for 1 hour at 37°C, 5% C02 under fully 
humidified conditions. Non-adherent cells were collected and washed twice in 
Hanks/Hepes. 
Recombinant human CSF and II. Recombinant GM-CSF was prepared and generous-
ly supplied by Schering (Kenilworth, New Jersey, U.S.A) and was used in a concentra-
tion of 10 ng/ml. Recombinant human hybridoma growth factor (rh-Il-6) was purified 
form E.coli (Brakenhoff et al, 1987), a generous gift from Dr L. Aarden (CLB, 
Amsterdam, The Netherlands). Rh-Il-6 was used in a concentration of 40 U/ml as 
defined by bioassay (Lansdorp et al, 1986). Recombinant human Interleukin-1 was 
purchased from Genzyme (Basel, Switzerland) and was used at 10 U /ml as defined by 
thymocyte assay. 
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Table 1 
Colony formation in response to GM-CSF and the combination of 
GM-CSF and Il-6 and for Il-l in MDS 
no MDS 
type 
1. RA 
2. RA 
3. RARS 
4. RARS 
5. RAEB 
6. RAEB 
7. RAEB 
8. RAEB 
9. RAEB 
10. RAEB 
11. RAEB 
12. RAEBt 
13. RAEBt 
14. RAEBt 
15. RAEBt 
16. CMML 
17. CMML 
18. CMML 
19. LTMDS 
20. LTMDS 
21. LTMDS 
22. LTMDS 
23. LTMDS 
MDS Mean 
SEM 
NBM 
1. 
2. 
3. 
4. 
5. 
NBM Mean 
SEM 
GM-CSF 
45.0 
5.2 
30.8 
133.2 
74.0 
o.o 
18.8 
16.0 
42.8 
26.8 
54.0 
4.0 
65.2 
8.0 
38.8 
0.0 
38.8 
34.5 
14.0 
38.4 
6.8 
1.2 
14.0 
30.9 
6.4 
37.2 
58.0 
40.6 
48.8 
45.2 
46.0 
3.6 
GM-CSF 
+Il-6 
128.0(2.8)1 
6.8(1.3) 
52.0(1.7) 
152.0 (1.1) 
114.0 (1.5) 
6.0(6.0) 
8.0(0.4) 
24.0(1.5) 
69.2(1.6) 
10.8(0.4) 
104.0(1.9) 
9.2(2.3) 
97.2(1.5) 
16.0(2.0) 
88.0(2.3) 
5.2(5.0) 
33.2(0.9) 
61.0(1.8) 
32.0(2.3) 
40.0(1.0) 
13.2 ( 1. 9) 
2.8(2.3) 
32.0(2.3) 
48.05 (1.6) 
9.4 
46.8(1.3) 
63.4(1.1) 
36.0(0.9) 
45.2(0.9) 
40.0(0.9) 
46.1(1.0) 
3.9 
GM-CSF 
+Il-l 
118.0 (2. 6) 
13.2(2.5) 
46.8(1.5) 
177.2(1.3) 
0.0(0.0) 
0.0(0.0) 
17.2(0.9) 
68.0(4.3) 
53.2(1.2) 
64.0(2.4) 
n.d2 
4.0(1.0) 
40.0(0.6) 
8.0(1.0) 
n.d 
1.2 (1.2) 
14.0(0.4) 
35.0(1.0) 
26.6(1.9) 
76.0(2.0) 
16.0(2.4) 
0.0(0.0) 
14.0 (1. 0) 
37.7(1.2) 
9.7 
36.0(1.0) 
58.6 (1. 0) 
41.4(1.0) 
45.2(0.9) 
46.8(1.0) 
45.6(1.0) 
3.7 
GM-CSF 
+Il-6 
+Il-l 
90.8(2.0) 
12.0(2.3) 
62.8(2.0) 
154.8 (1. 2) 
26.0(0.4) 
1.2(1.2) 
14.8(0.8) 
53.2(3.3) 
n.d 
22.8(0.9) 
n.d 
n.d 
n.d 
37.2(4.7) 
n.d 
2.8(2.8) 
8.0(0.2) 
44.0(1.3) 
n.d 
66.8(1.7) 
13. 2 ( 1. 9) 
1.2(1.0) 
n.d 
38.2(1.2) 
10.3 
38.9(1.0) 
60.1(1.0) 
39.2(1.0) 
43.2(0.9) 
45.2(1.0) 
43.2(0.9) 
2.9 
In parenthesis: the relative increase induced by the 
combination as compared to the GM-CSF effect only. IL-6 - GM-CSF 
n.d.: not determined. 
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Colony assay. Cultures were performed in the a-modification of Dulbecco's modified 
Eagles Medium (a-DMEM, Flow) containing 0.9% methylcellulose (Fluka Methocell 
MC), and supplemented with 20% FCS and 1% dialyzed Bovine Serum Albumin 
(BSA), 30 JLM lecithine, 0.1 JLM fully iron-saturated human transferrin, 100 JLM 
mercaptoethanol. Cultures were performed in 24-well plates (Costar), containing 2.5 x 
104 bone marrow cells per well (250 JLl). The cultures were incubated at 37 oc under 
fully humidified conditions of 5% C02 in air. Colonies ( = more than 50 cells) were 
counted on day 7, 10, 14, 18 and 22. Colonies were taken at random from several 
cultures and stained according to the May-Grunwald-Giemsa technique for subse-
quent morphological examination. 
Statistical analysis. Statistical evaluation of data was done with Wilcoxon's signed-
ranks test for two groups. 
RESULTS: 
The effect of GM-CSF stimulation on normal and MDS colony formation 
No spontaneous colony growth was observed in low-density, non-adherent, T-cell 
depleted normal or MDS bone marrow cells. Induction of colony formation by GM-
CSF is dose dependent. Plateau colony formation was achieved at concentrations of 5 
ng/ml rh-GM-CSF in both normal as well as MDS bone marrow cultures. However, 
colony numbers were decreased in 13/23 (56.5%) MDS cases as compared with 
normal bone marrow (table 1). 
Effect of Il-6 and Il-16 on colony growth 
Il-6 and Il-lB did not induce colony formation of fractionated normal bone marrow 
cells, neither singly nor together. As is shown in Fig 1 and Table 1, the addition of Il-
6 or Il-l had no effect on the GM-CSF induced colony formation of normal marrow 
progenitor cells. However, 11-6 enhanced the GM-CSF effect in 19/ 21 (90.5%) MDS 
cases, inducing an approximate two-fold increase in colony numbers (p< 0.01). In 3 
cases (Table 1: cases 7,10 and 17) colony numbers decreased in the presence of IL-6. 
In 11/21 (52.4%) cases an average two-fold enhancement of colony growth by Il-l 
was observed. Whereas in four cases an inhibition of the colony formation was 
observed (cases 5,13,17 and 22). 
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Figure 1: Effect of Il-6, Il-lj3 and their combination on GM-CSF induced MDS ma"ow 
(upper panel) and normal bone ma"ow (lower panel) colony formation. 
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In 9/21 cases Il-6 and Il-l both stimulated the GM-CSF induced colony formation. In 
case 17 Il-l and Il-6 both inhibited the colony formation, whereas in four cases 
opposite effects of Il-l and Il-6 were found. 
Role of accessory cells in the 11-6 enhancement 
The effects of Il-6 described above were obtained with T-cell depleted, non-adherent 
bone marrow cells. The effects of GM-CSF or the GM-CSF - Il-6 combination in 
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Fig 2. The e!Tects nf Cf..-1-CSF (light stipple! ;111d the c;I\1-CSF -II-fl 
combination (hc<n'Y stipple) on low-density (panel :\).low-density. 
adherent cell depleted (panel Bl. and low-density adherent cell. T-ccll 
depleted bone marrow cells (panel Cl of case 1. Data are expressed in 
percentages or maximal colony growth. 
MDS on respectively undepleted, adhe-
rent-cell depleted, and T-cell and adhe-
rent-cell depleted bone marrow cells are 
shown in Fig.2. The number of colonies 
formed by undepleted or adherent cell 
depleted bone marrow in response to 
GM-CSF was comparable to those for-
med by fully depleted bone-marrow cells 
in response to the combination of GM-
CSF - Il-6. This indicates that accessory cells apparently produce Il-6 endogeneously. 
II-6 effect on myeloid progenitor cells in the presence of high and low GM-CSF 
concentrations 
In order to determine whether Il-6 increases progenitor cell responsiveness to GM-
CSF, the activity of Il-6 was tested in the presence of high (supersaturating) concen-
trations of GM-CSF (100 ng/ml). Whereas a further increase of an already saturated 
GM-CSF dose did not improve the colony growth of MDS marrow, Il-6 had a definite 
enhancing effect at both GM-CSF concentration levels (Fig 3, left panel). To 
eliminate the possibility that the IL-6 effect is due to stimulation of endogeneously 
produced GM-CSF, a control was performed by adding Il-6 to normal bone marrow 
cultures under conditions of both sub-optimal (1 ng/ml) as well as saturated GM-CSF 
concentrations (10 ng/ml). No Il-6 effect was observed in in combination with either 
GM-CSF concentration (Fig 3, right panel). 
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Figure 3: Il-6 effect in the presence of a high (100 ngjml) dose GM-CSF in MDS (left 
panel) and a low dose (1 ngjml) GM-CSF in NBM (right panel) as compared with a 
normal GM-CSF concentration (10 ngjml). 
Kinetics of GM-CSF or GM-CSF - 11-6 induced colony formation 
Time course studies revealed two types of colony growth kinetics in response to GM-
CSF: (1) a growth pattern comparable with that of normal bone marrow (Fig 4, 
panels A and B), or (2) a delayed type of colony growth (panel D). Il-6 was found to 
augment GM-CSF induced colony numbers (panel Band D). In two cases (6 and 16) 
colony growth could be observed only in response to the GM-CSF - Il-6 combination 
(panel C). Il-6 did not affect MDS marrow colony growth kinetics: maximum colony 
numbers were found at the same day either in the presence or absence of Il-6. 
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Figure 4: Colony growth kinetics induced by either GM-CSF or the GM-CSF - Il-6 
combination in NBM (panel A), Refractory anaemia (RA) (panel B), RA with excess of 
blasts (RAEB) (panel C) or Leukemic transfonned MDS (LT-MDS) (panel D). 
The effect of delayed addition of GM-CSF and II-6 
In order to determine whether IL-6 is required at the initiation of the culture, IL-6 
was added at consecutively the beginning, at day 1, 2 and 6 of culture. The results 
indicate that a delayed addition of one to several days did not influence the effect of 
IL-6. However, a delay in GM-CSF addition of one to several days during continued 
IL-6 stimulation, resulted in a rapid decline in the number of colonies (Fig 5). 
Morphological features of the colony cells 
No clear differences in morphology of colony cells formed in response to either GM-
CSF or the GM-CSF - ll-6 combination were observed. In case 18 co-stimulation with 
ll-6 and GM-CSF revealed a 77% increase in colony numbers compared to stimulati-
on with GM-CSF only . 
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From both groups (GM-CSF - ll-6 as 
well as GM-CSF stimulation only) five 
colonies were randomly selected, and 
differential counts were performed on 
each of these colonies. In the GM-
CSF - IL-6 co-stimulated colonies 14.2% 
± 9.8 (M ± SD) of the cells were im-
mature (blasts and promyelocytes ), 
whereas in the GM-CSF stimulated 
colonies 8.5% ± 3.7 of the cells were 
immature (table 2). These differences 
are statistically insignificant. 
~ 
1j 
"' c 
~ 
~ 
'2 
0 
0 
u 
120 
100 
80 
60 
40 
20 
~~; IL-6 GM-CSF + IL 6 
dO d1 d2 d6 dO d1 d2 d6 
Figure 5. The effect of a delayed addition of 
either Il-6 or GM-CSF. 
Table 2 Differential counts of the colony cells formed in response to 
either GM-CSF or the GM-CSF - Il-6 combination in MDS (case 18) 
GM-CSF GM-CSF 
+Il-6 
% ± SD % ± SD 
blastsjpromyelocytes 8.5 ± 3.7 14.2 ± 9.8 
Myelocytes 28.5 ± 8.2 28.8 ± 10.5 
meta-myelocytes 26.2 ± 6.7 25.0 ± 6.6 
bands 10.8 ± 4.0 8.6 ± 1.5 
polymorphonuclears 25.3 ± 8.2 23.0 ± 13.2 
eosinophils 0.7 ± 0.7 0.4 ± 0.5 
monocytes 0.0 ± 0.0 0.0 ± o.-o 
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DISCUSSION 
In this study we investigated the effects of Il-6 and Il-l on the GM-CSF stimulated 
myeloid colony formation by low-density, non-adherent, T-cell depleted bone marrow 
cells of MDS patients and normal controls. Neither Il-6 nor Il-l were observed to 
induce the proliferation of myeloid progenitor cells on their own. Although these 
results are not concordant with those obtained by Caracciolo et al (1989a,b ), who 
found that Il-6 supported the proliferation of a small number of myeloid colonies, 
they agree with a number of other reports (Moore et al, 1987; Suda et al, 1988; Bot 
et al, 1989). Enhancement by Il-6 and Il-l of GM-CSF induced colony formation was 
observed in most MDS cases, in contrast to the lack of colony growth enhancement in 
normal bone marrow. Remarkably, the GM-CSF - IL-6 combination did induce 
colony formation in two cases in which neither factor alone was able to induce colony 
growth, indicating that both stimuli are required for proliferation of these progenitor 
cells. In cases with a reduced response to GM-CSF, neither IL-6, Il-l nor their 
combined activity resulted in a rise of the number of colonies into the normal range. 
This indicates that Il-6 and Il-l only potentiate the GM-CSF effect, but are not able 
to normalize a reduced response. Mayani et al (1989) previously reported an enhan-
cing effect by high-dose GM-CSF on myeloid colony formation of unfractionated 
MDS bone marrow, suggesting a reduced sensitivity of MDS progenitor cells for GM-
CSF. These results were not reproduced by more recent data collected by the same 
group (Baines et al, 1990) or by Carlo-Stella et al (1989). In addition, we did not find 
a high-dose GM-CSF effect. Since we could demonstrate that accessory cells can 
substitute for IL-6, the findings of Mayami et al may be due to endogenous release of 
Il-6 by accessory cells. Our findings also indicate that the Il-6 effect is due to an 
intrinsic disorder of the colony forming cell rather than to a reduced production of Il-
6 by MDS marrow accessory cells. 
We found that Il-6 did not affect the colony formation kinetics of MDS marrow. In 
cases with delayed colony growth kinetics, which we have reported to be a MDS 
characteristic (Schipperus et al, 1990), Il-6 was not able to shorten the delay in colony 
growth onset. Moreover, a delayed addition of GM-CSF of one day already totally 
abrogated the Il-6 effect, whereas the Il-6 effect is not influenced by a delay in 
administration. Therefore, our results are in agreement of those of Suda et al (1988) 
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and Caracciolo et al (1989), who found a proliferative TI-6 effect on late granulocyte-
macrophage progenitors, already responsive for GM-CSF, instead of acting like a 
priming factor as has been reported by others (Ikebuchi et al, 1987; Leary et al, 1988; 
Bot et al, 1989). Of the two groups of colony cells, which were stimulated either by 
GM-CSF or GM-CSF - IL-6 combination, morphological analysis revealed no 
significant differences. This indicates that increased colony formation is not accompa-
nied by an increased differentiation of colony cells. 
Although in most cases TI-6 and TI-l augmented the GM-CSF induced colony growth, 
in 3/21 cases TI-6 antagonized the GM-CSF induced colony formation. This was also 
observed in four cases with the TI-l - GM-CSF combination. This dual action of inter-
leukins has been described before, but is still difficult to explain. One possible 
explanation is that the effects of these interleukins depend on the conditions set by 
other substances present, i.e other growth factors or still undefined serum factors 
(Roberts, 1985). In other systems the effects of growth factors have been reported to 
depend on the developmental (differentiation) stage of the cells (Rennick et al, 1987). 
However, this does not be exclude the possibility that the production of inhibitors by 
residual accessory cells is induced in these cases. 
We present data indicating that TI-6, and in a lesser extent, TI-l enhance the GM-CSF 
induced myeloid colony formation of MDS bone marrow, as previously reported for 
leukemic myeloid cells and primitive normal haemopoietic progenitor cells. Everson 
et al, (1989) found that IL-6 and GM-CSF are potential growth factors for chronic 
myelomonocytic leukemia cells. These recent findings support our results. We 
observed augmentation of colony formation by TI-6 in all subtypes of MDS, suggesting 
that this response pattern is present throughout all stages of the disease. Furthermore, 
our results indicate that the reduced responsiveness for GM-CSF of the late granulo-
cyte-macrophage progenitor cells in MDS may be ameliorated by co-factors like TI-l 
or TI-6. 
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CHAPTER 7 
GENERAL DISCUSSION 
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MDS classification 
The myelodysplastic syndrome (MDS) classified according to the criteria proposed by 
the FAB-cooperative group encompasses a heterogeneous group of disorders with 
dyshemopoietic abnormalities in one or more cell lineages, with or without an 
increase in the percentage of bone marrow blast cells. Although, now generally 
accepted the classification has been the subject of much controversy for a number of 
reasons. First, none of the sub-types is wholly exclusive of the others. The RAs with 
or without an excess of blasts are a relatively homogeneous group. However, their 
distinction from the acute leukemias, especially erythroleukemia is arbitrary and 
unclear and perhaps separates unjustly diseases which are biologically an entity. 
Secondly, whithin one subtype considerable differences in terms of survival and risk of 
leukemic transformation may occur. In particular this is the case in acquired idiopa-
thic sideroblastic anemia (AISA) or refractory anemia with ringsideroblasts (RARS). 
Gatterman et al. (1990) have distinguished on cytomorphological grounds between 
pure sideroblastic anemia (PSA), which is confined to dyserythropoiesis and RARS, 
which is characterized by additional dysplastic features of granulopoiesis and/or 
megakaryopoiesis. Both PSA and RARS are diagnosed in the same MDS group 
(MDS 2 or RARS), but Gatterman and al. found striking differences in the risk of 
leukemic transformation between PSA and RARS in 94 patients (5 year cumulative 
rate 1.9 versus 48%). Overall survival was much better in PSA than in RARS (5 year 
cumulative chance 69% versus 19% ). Infections and hemorrhages were frequent 
causes of death in RARS but not in PSA The differences in terms of leukemic 
transformation and survival between cases with dysplastic features in one cell line and 
cases dysplastic in two or more cell lineages may apply to all MDS subtypes and not 
only to AISA cases. Saarni and Linman (1973) already made this distinction in their 
definition of the 'preleukemic syndrome' (PLS). Their criteria included the presence 
of dysplastic megakaryocytes and granulocytes as well as dyserythropoisis. Using these 
criteria a syndrome may be identified in which the incidence of acute leukemia ranges 
up to 45%. More recently Brito-Babapulle et al. (1987) have defined MDS with 
features of trilineage disease (TMDS). The authors looked for dysplastic features in 
erythroid, megakaryocytic and granulocytic lineages (i.e. PLS features) in the bone-
marrow of AML patients as evidence for pre-existing MDS. TMDS was found in 24 
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(15%) of the 160 consecutive cases of primary de novo AML, including two of 33 
cases of M1, four of 40 cases of M2, none of 18 cases of M3, five of 31 cases of M4, 
six of 30 cases of M5 and all of six cases of M6. They found that AML cases with 
TMDS differed from cases without in the occurrence of symptomatic cytopenias but 
also in lower rates of complete remission. One may conclude, at least in AML-M6 
cases, that biologically the leukemia represents the final stage of the malignant clone 
initiated already in the clinical stage of MDS. 
In chapter 2 we present results that support this view. We could demonstrate by 
double immunofluorescence studies (DIF) analysis that a population of TdT, myeloid-
antigen double positive (TdT + jMM +) cells was present in MDS cases with dyshemo-
poietic features in more than one lineage (RAEB and RAEBt). The frequency of 
MM + /TdT + cells was found to increase rapidly in the leukemic phase of the disease. 
In one patient the results of follow-up DIF studies showed that the frequency of 
MM + jTDT + cells decreased during remission, increased six months before relapse 
RAEB and finally to 35% in AML. Since these TdT + /MM + cells are extremely rare 
in normal bone marrow, they are considered to represent a subpopulation of the 
leukemic clone in AML (Adriaansen et al., 1990). In MDS MM + jTdT + cells 
probably represent the abnormal granulopoiesis, which may have already leukemic 
features. In this respect it is of interest that a MM + jTdT + subpopulation was 
present in a RARS case with an abnormal granulopoiesis, but absent in RARS cases 
without dysgranulopoiesis. In conclusion, double immunofluorescence analysis may be 
useful to detect abnormal myeloid cells in MDS and to monitor this subpopulation 
during disease progression. 
In vitro marrow cultures 
The colony forming capacities of the various progenitor cells are usually decreased in 
MDS patients (Greenberg and Mara, 1979; Chui and Clark, 1982; Greenberg et al., 
1983; Juvonen et al., 1985). Frequently an abnormal maturation of the colony cells is 
found (Golde and Cline, 1973; Spitzer et al., 1979; Verma et al., 1979). The main 
purpose of this study was to reveal the nature of the defect leading to the abnormal 
in vitro colony formation of the hemopoietic cells in MDS. Since survival, growth and 
differentiation of hemopoietic cells is dependent on hemopoietic growth factors or 
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colony stimulating factors we investigated the effects of these factors on the in vitro 
growth of MDS bone-marrow. The abnormal colony formation may be due to 1) an 
intrinsic defect of the progenitor cells, i.e. a decreased number of CSF receptors, a 
lower affinity of the receptors for CSF, or abnormalities in the intracellular CSF-
stimulus signal transduction; 2) an environmental defect, i.e. an abnormal growth 
factor production, either spontaneously or induced, by accessory cells or bone-marrow 
micro-environment. To eliminate the effects of accessory cells we depleted the bone-
marrow cells ofT-cells and adherent cells. Although these fractionated bone-marrow 
cell suspensions may still contain residual accessory cells, no spontaneous colony 
growth was observed. Moreover Il-1, a potential inducer of the production of 
hemopoietic growth factors by accessory cells, did not induce colony formation when 
added as a single factor to the bone-marrow cultures (chapter 6). Therefore we 
concluded that the bone marrow cells were, at least functionally, depleted of the cells 
capable of producing CSFs. 
In chapter 3 colony formation of normal and MDS bone marrow cells was tested in a 
liquid-agar double layer colony assay, adapted from the PHA-leukocyte feeder colony 
assay described by LOwenberg et al. (1980). The feeder layer was replaced by the 
conditioned medium of the giant tumor cell line (GCT-CM). Colony formation was 
found in all 7 NBM, 17 MDS and 5 AML cases. Colonies were found to be adherent 
or non-adherent to the agar underlayer. The adherent colonies consisted of terminally 
differentiated cells, whereas the non-adherent colonies comprised immature cells. We 
used the ratio adherent/non-adherent colonies as a measure for the maturation index 
of the colonies. The maturation index of NBM cases was high and that of AML cases 
low. MDS and LT-MDS cases had highly variable indices and their mean values were 
intermediate to that of NBM and AML. No apparent correlation was found between 
the colony maturation index and F AB type or clinical course of the MDS cases. When 
PHA was not added to the cultures, no or only a few colonies were observed in AML, 
LT-MDS and MDS cases with progressive disease. In the absence of PHA, the same 
number of colonies were found in MDS with a stable clinical course and NBM as in 
the presence of PHA. We concluded that PHA dependency for colony formation 
correlated with a higher number of blasts in the bone-marrow and probably with an 
impending leukemic transformation of the MDS. PHA may either function as: a) a 
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co-factor for CSF, required for MDS/AML progenitor cell proliferation, b) an 
inducer of the production of secondary factors necessary for MDS-progenitor 
proliferation, and c) an inducer of cell-cell contact necessary for the initiation of 
MDS/ AML progenitor-cell proliferation. Since initial cell-cell interaction seems to be 
a prerequisite for colony formation in the PHA-colony assay (Kluin-Nelemans, thesis 
1989, Pulsoni et al., 1989; Reilly et al., 1989) further experiments were performed in 
semi-solid media in order to exclude the influence of cell-cell interactions. 
First the response patterns and growth kinetics of colony-forming cells stimulated with 
Il-3, GM-CSF, G-CSF and GCT-CM were studied (chapter 4 and 5). Colony formati-
on was found in 23/23 MDS and LT-MDS cases with GCT-CM, in 19/21 (90.5%) 
with GM-CSF and 15/17 (88%) with GCT-CM stimulation. Colony numbers were 
below the normal range with GCT-CM stimulation in 9/23 (39%), with GM-CSF in 
13/21 (62%) and with IL-3 in 7/17 (41%) of the MDS cases (chapter 5). Therefore, 
single CSFs appear to stimulate colony formation by MDS bone marrow inadequately. 
Colony formation was found to be delayed in MDS as compared to NBM cultures 
(chapter 4). The delay in colony formation was most apparent in GCT-CM stimulated 
cultures. GCT-CM and G-CSF induced colony formation kinetics were found to be 
identical both in MDS and NBM cultures. GCT-CM colony formation activity could 
be neutralized by anti-G-CSF antibodies (chapter 5) indicating that the colony 
stimulating activity present in GCT-CM can be ascribed to G-CSF. In MDS cases 
with features of high risk disease (in terms of leukemic transformation and survival), 
a greater delay than in low risk cases was found. An increased time interval before 
progenitor cells begun to divide was found to cause the delayed colony formation. 
This was most apparent in the late (G-CSF responsive) progenitor compartment and 
progressed in parallel with disease progression. Cytogenetic analysis of the colony 
cells proved that these cells originated from the abnormal clone (chapter 4 and 5) 
and therefore we concluded that this growth pattern is a characteristic of the abnor-
mal clone. In normal bone marrow only the early progenitor cells are considered to 
be in GO (Lathja, 1979). Our results suggest that in MDS, progenitor cells in the 
relative late compartment as the CFU-G are more frequently dormant, i.e in GO of 
the cell cycle, than their normal counterparts. 
A possible explanation for the relative increase of dormant cells in the late progenitor 
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cell compartment in MDS may be an inadequate stimulation of these cells by single 
colony stimulating factors. In chapter 5 we therefore studied the effects of combinati-
ons of IL-3, GM-CSF and G-CSF on the in vitro growth of myeloid progenitors in 
MDS. The combination of Il-3 and GM-CSF did not enhance colony numbers above 
the sum of the colonies formed in the presence of the two factors alone (no synergis-
tic effect). Furthermore, colony numbers formed with the 11-3 - GM-CSF combination 
rarely exceeded the scores of the dominant factor (no additive effect). These results, 
which agree with those of Baines et al. (1990), suggest that these factors act on an 
identical progenitor population in MDS. In contrast, in NBM a partial additive effect 
of the IL-3 - GM-CSF combination was observed. This is in agreement with previous 
data indicating that IL-3 and GM-CSF stimulate overlapping, but distinct, progenitor 
cell populations (Emerson et al., 1988). A synergistic effect of the 11-3 - G-CSF 
combination was found in MDS but not in NBM. Therefore it appears that MDS 
myeloid progenitors require both IL-3 and G-CSF for optimal colony formation. We 
concluded that a pluripotent factor (as IL-3) should be combined with a later acting 
factor for an optimal colony stimulating effect in MDS. Again, (as the percentage 
dormant cells) this is a characteristic shared by early bone marrow progenitor cells 
(Caracciolo et al., 1989a). 
Apart from their activities on the lymphoid lineage, 11-1 and the pleiotropic cytokine 
IL-6 have been reported to act as co-stimulants for the growth of normal, primitive, 
hemopoietic progenitors (Moore et al., 1987; Leary et al., 1988). Since committed 
progenitor cells in MDS have many characteristics in common with normal primitive 
progenitor cells, 11-1 or 11-6 may act as co-stimulants on MDS progenitor cells. In 
chapter 6 the effects of IL-l and 11-6 on GM-CSF induced colony formation in NBM 
and MDS was studied. In normal bone marrow cultures, either stimulated with 
optimal or suboptimal doses of GM-CSF, no enhancing effect of 11-6 and 11-lB was 
detected. However, in the majority of the MDS cases an enhancing effect of IL-6 and 
IL-lB on the activity of GM-CSF was observed. No additional effect of a high GM-
CSF dose, either in the presence or absence of IL-6 was observed. These results 
suggest that 11-1 and 11-6 augment the sensitivity of MDS progenitor cells for GM-
CSF. Obviously this is not due to the induction of GM-CSF production by MDS 
progenitor cells or accessory cells, since the enhancing effect of IL-6 was still present 
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with high doses of GM-CSF. Possibly Il-l and Il-6 recruit MDS progenitor cells in a 
stage where they can respond to other factors. However, we found that a delayed 
administration of Il-6 did not influence its effect. Therefore, our results indicate that 
IL-6 acts on progenitor cells already responsive for GM-CSF, either by an augmenta-
tion the number of GM-CSF receptors on MDS progenitors as has been reported for 
the Il-l effect on early progenitors (Bartelmez and Stanley 1985) or by acting in a 
sequence following GM-CSF as have been reported by Caracciolo (1989b). 
How can these additive and synergistic effects of growth-factors on MDS progenitor 
cells be achieved? One explanation is that one CSF alters the progenitor cells so that 
they become responsive to stimulation by another, previously inactive CSF. The action 
mechanism may be, as with Il-l, the enhancement of CSF receptor expression. 
Alternative explanations may be the induction of rate limiting second messager 
systems or recruitment of the cells into a CSF responsive phase of cell-cycle. Why this 
two- or even three-signal system operates on committed MDS progenitors and only on 
primitive normal progenitor cells is unclear. Whereas all our data indicate that MDS 
committed progenitor cells are functionally immature and resemble, in that respect, 
normal pluripotent (early) progenitor cells, one explanation may be that this is 
primarily due to a maturation defect of the MDS clone, already detectable at the 
level of the progenitor cell compartment. However, as described in chapter 3, the 
delay in colony formation of MDS marrow was not associated with a relative increase 
of the GM-CSF responsive compartment, as would be expected in case of a relative 
increase of the earlier compartments. Moreover, Baines et al. (1988) have reported 
that the colony formation of purified CD34-positive cells in MDS is decreased as 
compared with CD34 normal bone marrow cells. These findings do not support the 
concept of a left shift in the progenitor cell compartment. 
The presence of a functional defect (i.e. an intrinsic disorder) of the progenitor cells 
in MDS may be another explanation. This intrinsic abnormality makes committed 
MDS progenitor cells functionally resemble normal early progenitor cells. Hypotheti-
cly this may be an adaptive processes of the MDS clone in order to compensate for 
an absolute or relative stem-cell deficit. 
The combined action of IL-6 and GM-CSF or Il-3 and G-CSF recruits both normal 
stem cells and MDS progenitor cells into cell-cycle. This may be a strong argument 
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for using these or other comparable combinations of growth factors in future clinical 
trials for MDS, since these growth factor combinations may effectively induce 
proliferation of residual normal stern cells and, at the same time, enhance differentia-
tion of the MDS clone. Continuous administration of these factors over longer 
periods of time are probably needed to initiate a lasting remission. However, since it 
is unknown whether CSFs can induce irreversible committrnent, there is a possible 
risk of stimulation one cell lineage at the cost of another. A more obvious drawback 
of combination therapy may be a more rapid induction of leukemic transformation as 
compared with the reported stimulation of proliferation of leukemic blast cells with 
GM-CSF alone (Herrmann et al., 1989). Well designed clinical trials have to provide 
us with the answers on these important questions. 
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SUMMARY 
Blood cell formation results from the continuous proliferation, differentiation and 
maturation of pluripotent hemopoietic stem cells located in the human bone marrow. 
In vitro culture assays, developed in the last twenty years, have enabled the identifica-
tion of the various pluripotent and committed progenitor cells present in human bone 
marrow by their capacity to form colonies of mature blood cells in vitro. Colony 
formation dependens on the presence of hemopoietic growth factors in the culture 
medium, which have become known as the colony stimulating factors (CSFs). At 
present a number of CSFs can be produced on a large scale through recombinant 
DNA technology and their biological activities have subsequently been defined. In 
chapter L 1 and 1.2 the general principles of hemopoiesis are introduced, i.e., the 
different models of stem cell renewal and commitment, the various in vitro clonogenic 
assays for normal as well as for leukemic colony forming cells and the effects of the 
CSF on progenitor cells and mature blood cells. 
The myelodysplastic syndrome (MDS) comprises a group of acquired disorders, which 
are characterized by an ineffective hemopoiesis resulting in cytopenia of one or more 
cell lineages. Cytogenetic and G-6-PD studies have demonstrated that MDS is a 
clonal disease of the hemopoietic stem celL The results of some studies suggest that 
normal hemopoiesis is replaced by the abnormal clone already in an early stage of 
the disease. Up to fourty percent of the MDS patients eventually develop an acute 
myeloblastic leukemia. The preleukemic nature of the MDS makes this syndrome of 
particular interest in the study of leukemogenesis. In chapter 1.3 the clinical, mor-
phological and in vitro growth characteristics of the MDS are introduced. 
In chapter 2 six patients with MDS (three RARS, two RAEB and one RAEBt) were 
studied using double immunofluorescence analysis (DIF) for the presence of terminal 
deoxynucleotidyl transferase (TdT) and myeloid-antigen (MM), such as CD13, CD14, 
CD15 and CD33 expression. TdT expression was found in 0.1 - 11% of the cells. In 
four cases (1 RAEBt, 2 RAEB and 1 RARS) 58 - 99% of the TdT + cells expressed 
the panmyeloid markers CD13 and/or CD33, whereas the precursor antigen CD34 
was present in 68 - 99% of the TdT + cells. Follow-up studies performed in two 
patients, that evolved into an acute myeloid leukemia (AML), showed in one patient 
an increase of MM + /TdT + cells from 11% in RAEBt to 25% in AML-M2. In the 
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other patient the percentage of MM + /TdT + cells was 0.1% at diagnosis, decreased 
during remission, increased to 0.2% before relapse RAEB and finally to 35% when 
AML-M2 emerged. These data indicate that MM + TdT + cells represent abnormal 
myeloid cells in MDS and their detection may be useful to monitor the abnormal 
myeloid subpopulation during disease progression. No MM + jTdT + cells were found 
in 2/3 RARS patients. In these patients no dysgranulopoietic features were found. In 
the other RARS case 5% MM + /TdT + cells were detected along with the presence 
of an abnormal granulopoiesis, suggesting that DIF staining can discriminate between 
RARS cases with and without an abnormal granulopoiesis. 
The abnormal hemopoiesis in MDS is reflected in an abnormal in vitro growth 
pattern of MDS bone marrow. Decreased or absent colony formation of erythroid and 
megakaryocytic progenitor cells is a typical finding. An abnormal granulocyte-
macrophage colony growth is often observed. However, the nature of the aberrant 
colony formation of MDS bone marrow in vitro is poorly understood. The main 
objective of this thesis was to study the possible defects leading to the abnormal in 
vitro colony formation of myeloid progenitor cells in MDS. In chapter 3 colony 
formation of normal (NBM), MDS, MDS in leukemic phase (LT-MDS) and leukemic 
(AML) bone marrow cells was studied in a modified PHA-leukocyte feeder colony 
assay, in which the feeder cells were replaced by the conditioned medium of the giant 
tumor cell line (GCT-CM) as a source of CSFs. It was found that in NBM and MDS 
marrows of patients with a stable clinical course optimal colony formation was 
observed with stimulation with GCT-CM alone, whereas LT-MDS, AML and MDS 
bone marrows of patients that ran a rapid progressive course were dependent on co-
stimulation with PHA and GCT-CM for colony formation. Thus, PHA dependency for 
colony formation may identify MDS cases with a more progressed disease. 
In chapter 4 the growth characteristics and kinetics of myeloid NBM and MDS 
progenitor cells stimulated with recombinant Il-3, GM-CSF and G-CSF were studied. 
Colony numbers were lower when stimulated with single recombinant CSF than with 
GCT-CM, although colony formation efficiency was high (at least 88% of cases). 
Colony formation was found to be delayed in MDS as compared with NBM. The 
delay in colony formation of the G-CFU was most apparent and in MDS cases with 
features of high risk disease (i.e., high leukemic transformation risk and short 
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survival). The delay in colony formation was found to be caused by a increased time 
interval before progenitor cells initiated division. These results suggest that committed 
progenitor cells in MDS marrow are relatively more quiescent (in the GO phase of 
cell cycle) than NBM progenitor cells and the time spent in Go increases with disease 
progression. 
In chapter 5 the effects on colony formation of the stimulation with combinations of 
recombinant 11-3, GM-CSF and G-CSF was studied. In NBM cultures an additive 
effect of the 11-3 - GM-CSF combination was observed, whereas no additive or 
synergistic effects of these factors were found in MDS. The response to G-CSF was 
reduced in MDS marrow as compared with NBM. This reduced effect could be 
ameliorated by 11-3, which acted synergisticly with G-CSF. These results indicate that 
a reduced colony growth of MDS marrow can be improved by the combined stimula-
tion with a pluripotent and a lineage restricted CSF. 
In chapter 6 the effects of 11-1 and 11-6 on the GM-CSF induced proliferation of 
myeloid progenitor cells in MDS was investigated. In NBM cultures, either stimulated 
with optimal or sub-optimal doses of GM-CSF, no enhancing effect of IL-6 or 11-1 was 
observed. However, in a majority of the MDS cases an enhancing effect of 11-1 and 11-
6 on GM-CSF induced colony formation was found. This enhancing effect was still 
present in the presence of high doses of GM-CSF, indicating that enhancement of 
colony formation was not mediated by the release of additional GM-CSF in the 
culture. These results suggest that 11-1 and 11-6 augment the sensitivity of progenitor 
cells for GM-CSF. However, a delayed addition of IL-6 of several days did not 
abrogate its effect, whereas an delayed administration of GM-CSF resulted in a fall in 
colony numbers. These results indicate that 11-6 acts on progenitor cells already 
responsive to GM-CSF. 11-6 may increase the number or affinity of the GM-CSF 
receptors or act in a sequence following the action of GM-CSF. 
In chapter 7 the results of these investigations are discussed in the context of the 
literature. 
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SAMENVATIING 
De vorming van bloed cellen is bet resultaat van de continue proliferatie, differentia-
tie en uitrijping van pluripotente bemopoietiscbe stamcellen en voorlopercellen, die 
zicb in bet menselijk beenmerg bevinden. In boofdstuk 1.1 en 1.2 worden de algeme-
ne principes van de bemopoiese geintroduceerd, waarbij ingegaan wordt op de 
verscbillende bestaande stamcelmodellen, de verscbillende in vitro kweeksystemen, 
die gebruikt worden om normale en leukemiscbe voorlopercellen te kweken en 
tenslotte de effecten van de CSFs op bemopoietiscbe voorlopercellen en rijpe bloed 
cell en. 
Het myelodysplastiscbe syndroom (MDS) is een verworven aandoening van de 
bemopoietiscbe stamcel, die resulteert in een ineffectieve bemopoiese. De ineffectivi-
teit van de bemopoiese komt tot uiting in een cytopenie van een of meerdere 
cellijnen (an ernie, leukopenie en trombopenie). De normale bemopoiese lijkt al in 
een vroeg stadium van de ziekte gebeel vervangen te zijn door de MDS kloon. De 
MDS-kloon wordt gekenmerkt door een neiging tot maligne ontaarding: ongeveer 
veertig procent van de MDS patienten krijgt uiteindelijk een AML. Deze eigenscbap 
maakt bet MDS uitermate interessant in bet kader van de bestudering van bet 
onstaan van leukemie, omdat meer inzicbt in de patbogenese van MDS kan leiden tot 
een betere kennis van bet onstaan van AML. In boofdstuk 1.3 wordt ingegaan op de 
kliniscbe, morpbologiscbe en in vitro groei eigenscbappen van MDS. 
In boofdstuk 2 worden zes MDS patienten bescbreven, waarvan bet beenmerg met 
bebulp van dubbelimmunofluorescentie tecbnieken geanalyseerd is. Gezocbt werd 
naar cellen, die zowel bet enzym terminale deoxynucleotidyl transferase (TdT) als 
myeloid-antigenen als CD13, CD14, CD15 en CD33 tot expressie bracbten 
(MM + /TdT + ). TdT expressie werd gevonden in 0,1 - 11% van de cellen. Bij vier 
patienten (1 RAEBt, 2 RAEB en 1 RARS) bleken 58 - 99% van de TdT + cellen de 
panmyeloide-antigenen CD13 en/of CD33 tot expressie te brengen, terwijl bet 
precursor antigeen CD34 in 26 - 99% van de TdT+ cellen aanwezig was. Vervolg 
studies in twee patienten lieten een duidelijke toename van de MM + /TdT + cell en 
zien van 11% naar 25% en 0,1% naar 35% in respectievelijk de MDS and AML fase. 
Bij twee van de drie RARS patienten werden geen MM + /TdT + cellen gevonden. 
Deze twee patienten vertoonden geen afwijkingen in de granulopoiesis. In de andere 
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RARS patient konden 5% MM + /TdT + cell en worden aangetoond en deze patient 
had inderdaad een abnormale granulopoiesis. Uit deze gegevens kan geconcludeerd 
worden dat dubbel-immunofluorescentie analyses de mogelijkheid verschaffen om een 
abnormale subpopulatie myeloide cellen, aanwezig in MDS beenmerg, te detecteren 
en te vervolgen gedurende de verschillende fases van de ziekte. 
De abnormale hemopoiese bij MDS patienten vindt zijn weerslag in een abnormaal in 
vitro groeipatroon van MDS beenmerg. Over het algemeen is de kolonievorming van 
erythroide, megakaryocytaire en myeloide voorlopercellen afgenomen of afwezig. De 
oorzaak hiervan is onbekend. Ret belangrijkste doel van het onderzoek, beschreven in 
dit proefschrift, is het achterhalen van afwijkingen in MDS beenmerg, die kunnen 
leiden tot deze veranderde groeipatronen. 
In hoofdstuk 3 worden de groeieigenschappen beschreven van myeloide MDS 
voorlopercellen in een kweeksysteem, dat door de groep van LOwenberg speciaal 
ontwikkeld is voor leukemisch beenmerg (PHA-lf-assay). In dit kweeksysteem wordt 
de proliferatie van voorlopercellen zowel door CSFs als door phytohemagglutinine 
(PHA) gestimuleerd. Bij normaal beenmerg en beenmerg van MDS patienten met 
een stabiel klinisch beloop bleek de koloniegroei optimaal gestimuleerd te worden 
door CSF aileen. Echter, bij AML, leukemisch getransformeerde MDS, en MDS 
patienten met een progressief klinisch beloop, bleek PHA naast CSF onontbeerlijk te 
zijn voor koloniegroei. Geconcludeerd kan worden dat de afhankelijkheid van PHA 
voor in vitro koloniegroei een eigenschap is van beenmerg van MDS patienten met 
een meer progressief beloop, of een grotere kans op het ontwikkelen van een AML. 
In hoofdstuk 4 wordt de groei kinetiek van hemopoietische voorlopercellen in MDS 
beenmerg, na stimulatie met recombinant interleukine-3 (IL-3), granulocyte-macrop-
hage colony-stimulating factor (GM-CSF) en granulocyte-CSF (G-CSF) beschreven. In 
meer dan 88% van de gevallen werd koloniegroei gestimuleerd door een van deze 
factoren. De kolonie-aantallen waren echter veelal lager dan in kweken gestimuleerd 
met GCT-CM (welke meerdere groeifactoren bevat). Een vertraagde koloniegroei 
van MDS beenmerg werd gevonden, welke het meest uitgesproken was bij granulocy-
taire voorlopercellen (G-CFU). Tevens was de vertraagde groei meer uitgesproken bij 
MDS patienten met in het beenmerg meer dan 10 % blasten, complexe cytogeneti-
sche afwijkingen, of een gedocumenteerde leukemische ontaarding. De vertraagde 
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koloniegroei bleek veroorzaakt te worden doordat de voorlopercellen een latere 
aanvang maakten met de deling. Deze resultaten suggereren dat gecommiteerde voor-
lopercellen in MDS beenmerg relatief langer in rust zijn (in de GO fase van de eel 
cyclus) in vergelijking hun normale tegenvoeters. 
In hoofdstuk 5 worden de effecten van stimulatie met combinaties van CSFs op de 
koloniegroei van MDS beenmerg beschreven. Een duidelijk synergistisch effect van de 
combinatie Il-3 en G-CSF op MDS myeloide voorlopercellen werd gevonden, terwijl 
dit effect niet waameembaar was bij normaal beenmerg. Deze resultaten suggereren 
dat myeloide voorlopercellen in MDS beenmerg meerdere CSFs nodig hebben voor 
een optimale stimulatie (waarschijnlijk een progressie factor gecombineerd met een 
differentiatie factor). Dit is een eigenschap die ook beschreven is voor normale 
pluripotente voorlopercellen en suggereerd een functionele onrijpheid van myelodys-
plastische myeloide voorlopercellen. 
In hoofdstuk 6 worden de effecten van 11-1 and 11-6 op myeloide voorlopercellen in 
MDS beenmerg beschreven. 11-1 en 11-6 stimuleren zelf geen koloniegroei, maar 
kunnen de repons op een tweede CSF vergroten. Bij normale beenmerg kweken werd 
geen effect van de beide interleukines gezien in combinatie met GM-CSF. Ben 
duidelijk stimulerend effect van 11-1 en 11-6 op de koloniegroei van MDS beenmerg 
werd echter wel gevonden. Ook in de aanwezigheid van een tienvoudige concentratie 
GM-CSF was dit stimulerend effect aanwezig. Dit geeft aan dat de stimulatie niet 
wordt veroorzaakt door een extra productie van GM-CSF. Waarschijnlijk verhogen Il-
l and 11-6 de gevoeligheid van MDS voorlopercellen voor GM-CSF. Identieke 
resultaten werden verkregen wanneer 11-6 pas na enkele dagen aan de kweken werd 
toegevoegd, wat impliceert dat 11-6 waarschijnlijk voorlopercellen stimuleert, die al 
gevoelig zijn voor GM-CSF. Geconcludeerd kan worden dat in MDS, myeloide 
voorlopercellen verminderd gevoelig zijn voor GM-CSF. Deze verminderde gevoelig-
heid kan niet verholpen worden met behulp van zeer hoge doseringen GM-CSF, maar 
wel gedeeltelijk door middel van co-stimulatie met 11-6. 
In hoofdstuk 7 worden de resultaten besproken in samenhang met recente literatuur 
gegevens. 
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ABBREVIATIONS 
AET 
AI SA 
ALIP 
AML 
BFU-E 
BPA 
CAFC 
CD 
CFU-blast 
CFU-E 
CFU-Eo 
CFU-G 
CFU-GEMM 
CFU-GM 
CFU-M 
CFU-Meg 
CM 
CMML 
CSF 
ECGF 
Epo 
FAB 
FCS 
GCT-CM 
G-CSF 
GM-CSF 
HGF 
HIM 
IL 
LT 
LT-MDS 
McAb 
M-CSF 
MDS 
MM 
NBM 
PDGF 
PHA 
PHSC 
PLS 
PSA 
RA 
RAEB 
RAEBt 
RARS 
TdT 
TGF 
T-MDS 
TNF 
4-HC 
2-aminoethylthiouronium bromide hydrobromide 
acquiered idiopathic sideroblastic anemia 
abnormal localization of immature precursors 
acute myeloid leukemia 
burst forming unit -erythroid 
burst promoting activity 
coblestone area forming cell 
cluster of differentiation 
colony forming unit -blast cells 
colony forming unit-erythroid 
colony forming unit-eosinophil 
colony forming unit-granulocyte 
colony forming unit -granulocyte-erythroid-macrophage-megakaryocyte 
colony forming unit-granulocyte-macrophage 
colony forming unit-macrophage 
colony forming unit-megakaryocyte 
conditioned medium 
chronic myelomonocytic leukemia 
colony-stimulating factor 
endothelial cell growth factor 
erythropoietin 
French-American-British cooperative group 
fetal calf serum 
giant cell tumor cell-line conditioned medium 
granulocyte-colony stimulating factor 
granulocyte-macrophage-colony stimulating factor 
hemopoietic growth factor 
hemopoietic inductive environment 
interleukin 
lymphotoxin 
leukemic transformed myelodysplastic syndrome 
monoclonal antibody 
macrophage-colony stimulating factor 
myelodysplastic syndrome 
myeloid marker 
normal bone marrow 
platelet derived growth factor 
phytohemagglutinin 
pluripotent hemopoietic stem cell 
preleukemic syndrome 
pure sideroblastic anemia 
refractory anemia 
refractory anemia with excess of blasts 
refractory anemia with excess of blasts in transformation 
refractory anemia with ringsideroblasts 
terminal deoxynucleotidyl transferase 
transforming growth factor 
trilineage myelodysplasia 
tumor necrosis factor 
4-hydroperoxycyclophosphamid 
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